Access DB# _____

SEARCH REQUEST FORM

58742

Scientific and Technical Information Center

Requester's Full Name: BEN LACKEY Examiner #: _____ Date: 1/22/02
Art Unit: 1626 Phone Number 305-1889 Serial Number: 09/734,608
Mail Box and Bldg/Room Location: CM1 3E11 Results Format Preferred (circle): PAPER DISK E-MAIL

If more than one search is submitted, please prioritize searches in order of need. MEJ

****

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: Substituted norbornylamine derivs., processes for prep. and use etc

Inventors (please provide full names): Heinelt et al.

Earliest Priority Filing Date: 12/14/99

For Sequence Searches Only *Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.*



A is alkylene

S1 is free electron pair or C1-4 alkyl

S2 is C1-4 alkyl or H

B is an alkyne



elected species

****

STAFF USE ONLY	Type of Search		Vendors and cost where applicable	
Searcher: K. Fuchs	NA Sequence (#)		STN	←
Searcher Phone #:	AA Sequence (#)		Dialog	
Searcher Location:	Structure (#)	1	Questel/Orbit	
Date Searcher Picked Up:	Bibliographic		Dr.Link	
Date Completed: 1/25/02	Litigation		Lexis/Nexis	
Searcher Prep & Review Time: 20	Fulltext		Sequence Systems	
Clerical Prep Time:	Patent Family		WWW/Internet	
Online Time: 17	Other		Other (specify)	

PTO-1590 (8-01)

=> FILE REG
FILE 'REGISTRY' ENTERED AT 11:06:54 ON 25 JAN 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

STRUCTURE FILE UPDATES: 24 JAN 2002 HIGHEST RN 386206-85-5
DICTIONARY FILE UPDATES: 24 JAN 2002 HIGHEST RN 386206-85-5

TSCA INFORMATION NOW CURRENT THROUGH July 7, 2001

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Calculated physical property data is now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=> FILE HCAPLUS
FILE 'HCAPLUS' ENTERED AT 11:07:00 ON 25 JAN 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 25 Jan 2002 VOL 136 ISS 4
FILE LAST UPDATED: 23 Jan 2002 (20020123/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

This file supports REG1stRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

HCAplus now provides online access to patents and literature covered in CA from 1907 to the present. Bibliographic information and abstracts were added in 2001 for over 3.8 million records from 1907-1966.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

=> D QUE
L28 STR



155 structures from the query

NODE ATTRIBUTES:
NSPEC IS R AT 8
NSPEC IS R AT 9
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 17

STEREO ATTRIBUTES: NONE
L30 155 SEA FILE=REGISTRY SSS FUL L28
L31 15 SEA FILE=HCAPLUS ABB=ON L30
L32 15 SEA FILE=HCAPLUS ABB=ON L31(L)(PREP OR SPN OR IMF)/RL

15 CA references

=> D L32 1-15 ALL HITSTR

L32 ANSWER 1 OF 15 HCAPLUS COPYRIGHT 2002 ACS
AN 2001:452994 HCAPLUS
DN 135:46327
TI Method for the production of substituted norbornylamino derivatives, medicaments containing said compounds and the use thereof as a medicament or a diagnostic reagent
IN Heinelt, Uwe; Lang, Hans-Jochen; Kleemann, Heinz-Werner; Schwark, Jan-Robert; Wirth, Klaus; Jansen, Hans-Willi
PA Aventis Pharma Deutschland G.m.b.H., Germany
SO PCT Int. Appl., 74 pp.
CODEN: PIXXD2
DT Patent
LA German
IC ICM C07C211-38
ICS C07C217-56; A61K031-137
CC 30-10 (Terpenes and Terpenoids)
Section cross-reference(s): 1
FAN.CNT 1

applicant

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001044164	A1	20010621	WO 2000-EP12107	20001201

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,

BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

DE 19960204 A1 20010628 DE 1999-19960204 19991214
US 2001023257 A1 20010920 US 2000-734008 20001212
PRAI DE 1999-19960204 A 19991214
OS MARPAT 135:46327
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to substituted norbornylamino derivs. contg. exo-configured nitrogen and an endo-annelated pentacyclic ring and exo-configured nitrogen and an exo-annelated pentacyclic ring, e.g. I [R1, R2, R3, R4, R5 = H, OH, F, Cl, Br, I, CN, NO2, amidino, CO2R11, CONR11R12, SOrR11, SOsNR11R12, C1-4-alkyl, C1-4-alkoxy, C1-4-alkoxyalkyl, C1-4-alkoxyalkoxy, hydroxy-C1-4-alkyl, C3-7-cycloalkoxy, (un)substituted OPh (up to three of F, Cl, Br, OMe), NH2, C1-4-alkylamino, di(C1-4-alkyl)amino, amino-C1-4-alkyl, di(C1-4-alkyl)amino-C1-4-alkyl, C1-4-alkylamino-C1-4-alkyl; R1R2, R2R3, R3R4, R4R5 = O(CH2)nO; R11, R12 = H, ; A = C1-4-alkylene; B = (un)substituted C5-7-ring with :O, OH, C1-4-alkoxy, C1-4-alkyl; S1 = free electron pair, C1-4-alkyl; S2 = C1-4-alkyl, H; when S1 and S2 are both alkyl, the ammonium counter ion, X- = pharmaceutically acceptable salt or trifluoroacetate; n = 1, 2; r = 0 - 2; s = 1, 2] and II. Thus, I.cntdot.HCl [R1 = R3 - R5 = S2 = H, R2 = OMe, A = B = CH2, S1 = free electron] was prepd. from exo,endo-octahydro-4,7-methanoinden-5-ylamine (III) via condensation of 3-MeOC6H4CHO in PhMe contg. catalytic p-TsOH followed by redn. with NaBH4 in MeOH and acidification with HCl in MeOH. Said derivs. are esp. suitable as anti-hypertensive agents for reducing or preventing ischemia-induced damage, as medicaments for use in surgical procedures for treating ischemias of the nervous system, of a cerebrovascular accident and of a cerebral edema. The derivs. are also suitable for treating shock, an impaired respiratory impulse, snoring, or for use as a laxative, as an agent against ectoparasites, in the prophylaxis of gall stones, as an anti-atherosclerotic agent, as an agent for treating late complications of diabetes, or for treating cancerous illnesses, fibrotic disorders, endothelial dysfunction and organ hypertrophies and hyperplasias. Said derivs. act as inhibitors of the cellular sodium-proton-antiporter. They also influence serum lipoproteins and can thus be used in the prophylaxis and reversal of atherosclerotic changes. Thus, I.cntdot.HCl [R1 = R3 - R5 = S2 = H, R2 = OMe, A = B = CH2, S1 = free electron] was tested for its diuretic (none orally in rats) and NHE3 activity (IC50 = 0.81 .mu.M).

ST pentacyclic annelated norbornylamine deriv prepn biol activity; methanoindenylamine octahydro deriv prepn condensation benzaldehyde methoxybenzaldehyde; diuretic pentacyclic annelated norbornylamine deriv prepn; NHE3 activity diuretic pentacyclic annelated norbornylamine deriv; sodium proton antiporter inhibitor pentacyclic annelated norbornylamine deriv prepn; serum lipoprotein regulator pentacyclic annelated norbornylamine deriv prepn; atherosclerotic change medicament pentacyclic annelated norbornylamine deriv prepn; antihypertensive pentacyclic annelated norbornylamine deriv prepn

IT Structure-activity relationship
(diuretic; prepn. of substituted norbornylamino derivs. for use as a antihypertensive agent or a diagnostic reagent)

IT Transport proteins
RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
(hydrogen ion-sodium-exchanging, cellular antiporter inhibitor; prepn. of substituted norbornylamino derivs. for use as a antihypertensive

agent or a diagnostic reagent)

IT Antihypertensives
Diuretics
(prepn. of substituted norbornylamino derivs. for use as a antihypertensive agent or a diagnostic reagent)

IT Atherosclerosis
(prophylaxis and reversal medicaments; prepn. of substituted norbornylamino derivs. for use as a antihypertensive agent or a diagnostic reagent)

IT Lipoproteins
RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
(serum, regulators; prepn. of substituted norbornylamino derivs. for use as a antihypertensive agent or a diagnostic reagent)

IT **344576-13-2P 344576-14-3P 344576-96-1P**
RL: BAC (Biological activity or effector, except adverse); PUR (Purification or recovery); **SPN (Synthetic preparation)**; THU (Therapeutic use); BIOL (Biological study); **PREP (Preparation)**; USES (Uses)
(prepn. of substituted norbornylamino derivs. for use as a antihypertensive agent or a diagnostic reagent)

IT **344577-00-0P**
RL: BAC (Biological activity or effector, except adverse); RCT (Reactant); **SPN (Synthetic preparation)**; THU (Therapeutic use); BIOL (Biological study); **PREP (Preparation)**; USES (Uses)
(prepn. of substituted norbornylamino derivs. for use as a antihypertensive agent or a diagnostic reagent)

IT **344576-09-6P 344576-10-9P 344576-11-0P**
344576-12-1P 344576-16-5P 344576-17-6P
344576-18-7P 344576-19-8P 344576-20-1P
344576-21-2P 344576-22-3P 344576-23-4P
344576-24-5P 344576-25-6P 344576-26-7P
344576-27-8P 344576-28-9P 344576-30-3P
344576-32-5P 344576-34-7P 344576-35-8P
344576-37-0P 344576-38-1P 344576-40-5P
344576-41-6P 344576-42-7P 344576-43-8P
344576-44-9P 344576-45-0P 344576-46-1P
344576-47-2P 344576-48-3P 344576-49-4P
344576-50-7P 344576-51-8P 344576-52-9P
344576-53-0P 344576-54-1P 344576-56-3P
344576-57-4P 344576-59-6P 344576-60-9P
344576-62-1P 344576-63-2P 344576-64-3P
344576-65-4P 344576-66-5P 344576-67-6P
344576-68-7P 344576-69-8P 344576-70-1P
344576-71-2P 344576-72-3P 344576-73-4P
344576-74-5P 344576-75-6P 344576-76-7P
344576-77-8P 344576-78-9P 344576-80-3P
344576-82-5P 344576-83-6P 344576-84-7P
344576-85-8P 344576-86-9P 344576-87-0P
344576-88-1P 344576-94-9P 344576-95-0P
344577-06-6P 344577-07-7P 344577-08-8P
344577-09-9P 344577-10-2P 344577-11-3P
344577-12-4P 344577-13-5P 344577-14-6P
344577-15-7P 344577-16-8P 344577-17-9P
RL: BAC (Biological activity or effector, except adverse); **SPN (Synthetic preparation)**; THU (Therapeutic use); BIOL (Biological study); **PREP (Preparation)**; USES (Uses)
(prepn. of substituted norbornylamino derivs. for use as a antihypertensive agent or a diagnostic reagent)

IT 77-73-6, Dicyclopentadiene 85-41-6, Phthalimide 99-61-6, 3-Nitrobenzaldehyde 99-64-9, 3-(Dimethylamino)benzoic acid 100-83-4,

3-Hydroxybenzaldehyde 395-44-8, 2-(Trifluoromethyl)benzyl bromide 456-48-4, 3-Fluorobenzaldehyde 586-37-8 587-04-2, 3-Chlorobenzaldehyde 591-31-1, 3-Methoxybenzaldehyde 625-95-6, 3-Iodotoluene 1798-09-0, 3-Methoxyphenylacetic acid 3132-99-8, 3-Bromobenzaldehyde 4453-90-1, Benzonorbornadiene 6482-24-2, 1-Bromo-2-methoxyethane 10516-71-9, 3-(3-Methoxyphenyl)propionic acid 13380-94-4, Tricyclo[5.2.1.02,6]decan-8-one 24964-64-5, 3-Cyanobenzaldehyde 32085-88-4, 3,5-Difluorobenzaldehyde 72403-63-5, exo-5-Isothiocyanato-5,6-dihydro-endo-dicyclopentadiene 344577-05-5
RL: RCT (Reactant)
(prepn. of substituted norbornylamino derivs. for use as a antihypertensive agent or a diagnostic reagent)

IT 7142-70-3P 18530-42-2P 18530-46-6P, exo,endo-Octahydro-4,7-methanoinden-5-ylamine 18530-47-7P, exo,exo-Octahydro-4,7-methanoinden-5-ylamine 49617-83-6P 62624-26-4P, exo-(1,2,3,4-Tetrahydro-1,4-methanonaphthalin-2-yl)amine 65839-06-7P 73244-50-5P 73335-94-1P, endo,exo-Octahydro-4,7-methanoinden-5-ylamine 114062-14-5DP, isomers 344576-89-2P 344576-90-5P 344576-92-7P 344576-93-8P 344576-97-2P 344576-99-4P **344577-01-1P 344577-02-2P 344577-03-3P 344577-04-4P 344577-19-1P** 344920-95-2P, exo,endo-Octahydro-4,7-methanoinden-5-ylamine trifluoroacetate 344920-96-3P, endo,endo-Octahydro-4,7-methanoinden-5-ylamine 344920-97-4P, exo,exo-Octahydro-4,7-methanoinden-5-ol 344920-98-5P, exo,endo-(Decahydro-1,4-methanonaphthalin-2-yl)amine
RL: RCT (Reactant); **SPN (Synthetic preparation)**; **PREP (Preparation)**
(prepn. of substituted norbornylamino derivs. for use as a antihypertensive agent or a diagnostic reagent)

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Druckrey, E; US 4024274 A 1977 HCAPLUS
(2) Hoechst Ag; EP 0825178 A 1998 HCAPLUS
(3) Magainin Pharma; WO 9640151 A 1996 HCAPLUS

IT **344576-13-2P 344576-14-3P 344576-96-1P**
RL: BAC (Biological activity or effector, except adverse); PUR (Purification or recovery); **SPN (Synthetic preparation)**; THU (Therapeutic use); BIOL (Biological study); **PREP (Preparation)**; USES (Uses)
(prepn. of substituted norbornylamino derivs. for use as a antihypertensive agent or a diagnostic reagent)

RN 344576-13-2 HCAPLUS
CN 4,7-Methano-1H-inden-5-amine, octahydro-N-[(3-methoxyphenyl)methyl]-, hydrochloride, (3aR,4S,5R,7S,7aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 344576-14-3 HCAPLUS
CN 4,7-Methano-1H-inden-5-amine, octahydro-N-[(3-methoxyphenyl)methyl]-, hydrochloride, (3aS,4R,5S,7R,7aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



● HCl

RN 344576-96-1 HCAPLUS
CN 4,7-Methano-1H-inden-5-amine, octahydro-N-[(3-methoxyphenyl)methyl]-, hydrochloride, (3aR,4S,5R,7S,7aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



HCl

IT **344577-00-0P**
RL: BAC (Biological activity or effector, except adverse); RCT (Reactant); **SPN (Synthetic preparation)**; THU (Therapeutic use); BIOL (Biological study); **PREP (Preparation)**; USES (Uses)
(prepn. of substituted norbornylamino derivs. for use as a antihypertensive agent or a diagnostic reagent)
RN 344577-00-0 HCAPLUS
CN Benzoic acid, 3-[[[(3aR,4S,5R,7S,7aR)-octahydro-4,7-methano-1H-inden-5-yl]amino]methyl]-, butyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT **344576-09-6P 344576-10-9P 344576-11-0P**
344576-12-1P 344576-16-5P 344576-17-6P
344576-18-7P 344576-19-8P 344576-20-1P
344576-21-2P 344576-22-3P 344576-23-4P
344576-24-5P 344576-25-6P 344576-26-7P
344576-27-8P 344576-28-9P 344576-30-3P
344576-32-5P 344576-34-7P 344576-35-8P
344576-37-0P 344576-38-1P 344576-40-5P
344576-41-6P 344576-42-7P 344576-43-8P
344576-44-9P 344576-45-0P 344576-46-1P
344576-47-2P 344576-48-3P 344576-49-4P
344576-50-7P 344576-51-8P 344576-52-9P
344576-53-0P 344576-54-1P 344576-56-3P
344576-57-4P 344576-59-6P 344576-60-9P
344576-62-1P 344576-63-2P 344576-64-3P
344576-65-4P 344576-66-5P 344576-67-6P
344576-68-7P 344576-69-8P 344576-70-1P
344576-71-2P 344576-72-3P 344576-73-4P
344576-74-5P 344576-75-6P 344576-76-7P
344576-77-8P 344576-78-9P 344576-80-3P
344576-82-5P 344576-83-6P 344576-84-7P
344576-85-8P 344576-86-9P 344576-87-0P
344576-88-1P 344576-94-9P 344576-95-0P
344577-06-6P 344577-07-7P 344577-08-8P
344577-09-9P 344577-10-2P 344577-11-3P
344577-12-4P 344577-13-5P 344577-14-6P
344577-15-7P 344577-16-8P 344577-17-9P
RL: BAC (Biological activity or effector, except adverse); **SPN (Synthetic preparation)**; THU (Therapeutic use); BIOL (Biological study); **PREP (Preparation)**; USES (Uses)
(prepn. of substituted norbornylamino derivs. for use as a antihypertensive agent or a diagnostic reagent)
RN 344576-09-6 HCAPLUS
CN 4,7-Methano-1H-inden-5-amine, N-[(3-chlorophenyl)methyl]octahydro-, hydrochloride, (3aR,4S,5R,7S,7aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 344576-10-9 HCAPLUS
CN 4,7-Methano-1H-inden-5-amine, N-[(3-fluorophenyl)methyl]-3a,4,5,6,7,7a-hexahydro-, (3aR,4S,5R,7S,7aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 344576-11-0 HCAPLUS
CN 4,7-Methano-1H-inden-5-amine, 3a,4,5,6,7,7a-hexahydro-N-[(3-methoxyphenyl)methyl]-, (3aR,4S,5R,7S,7aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 344576-12-1 HCAPLUS
CN 4,7-Methano-1H-inden-2-ol, octahydro-5-[[(3-methoxyphenyl)methyl]amino]-, (3aR,4S,5R,7S,7aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 344576-16-5 HCAPLUS
CN 4,7-Methano-1H-inden-5-amine, octahydro-N-[(3-methoxyphenyl)methyl]-, hydrochloride, (3aR,4R,5R,7R,7aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 344576-17-6 HCAPLUS
CN 4,7-Methano-1H-inden-5-amine, octahydro-N-[(3-methoxyphenyl)methyl]-, hydrochloride, (3aR,4S,5S,7S,7aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 344576-18-7 HCAPLUS
CN 4,7-Methano-1H-inden-5-amine, octahydro-N-[(3-methoxyphenyl)methyl]-, hydrochloride, (3aR,4R,5S,7R,7aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 344576-19-8 HCAPLUS
CN 4,7-Methano-1H-inden-5-amine, N-[(3-fluorophenyl)methyl]octahydro-, hydrochloride, (3aR,4S,5R,7S,7aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 344576-20-1 HCAPLUS
CN 4,7-Methano-1H-inden-5-amine, N-[(3,5-difluorophenyl)methyl]octahydro-, hydrochloride, (3aR,4S,5R,7S,7aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 344576-21-2 HCAPLUS
CN 4,7-Methano-1H-inden-5-amine, octahydro-N-[1-(3-methoxyphenyl)ethyl]-, hydrochloride, (3aR,4S,5R,7S,7aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 344576-22-3 HCAPLUS
CN 4,7-Methano-1H-inden-5-amine, N-[(3-bromophenyl)methyl]octahydro-, hydrochloride, (3aR,4S,5R,7S,7aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 344576-23-4 HCAPLUS
CN Benzoic acid, 3-[[[(3aR,4S,5R,7S,7aR)-octahydro-4,7-methano-1H-inden-5-yl]amino]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 344576-24-5 HCAPLUS
CN 4,7-Methano-1H-inden-5-amine, octahydro-N-[[3-(2-methoxyethoxy)phenyl]methyl]-, hydrochloride, (3aR,4S,5R,7S,7aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 344576-25-6 HCAPLUS
CN 4,7-Methano-1H-inden-5-amine, octahydro-N-[(3-iodophenyl)methyl]-,

hydrochloride, (3aR,4S,5R,7S,7aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 344576-26-7 HCAPLUS
CN Benzonitrile, 3-[[[(3aR,4S,5R,7S,7aR)-octahydro-4,7-methano-1H-inden-5-yl]amino]methyl]-, monohydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 344576-27-8 HCAPLUS
CN Benzoic acid, 3-[[[(3aR,4S,5R,7S,7aR)-octahydro-4,7-methano-1H-inden-5-yl]amino]methyl]-, methyl ester, hydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 344576-28-9 HCAPLUS
CN Benzenemethanol, 3-[[[(3aR,4S,5R,7S,7aR)-octahydro-4,7-methano-1H-inden-5-yl]amino]methyl]-, hydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 344576-30-3 HCAPLUS
CN Benzamide, 3-[[[(3aR,4S,5R,7S,7aR)-octahydro-4,7-methano-1H-inden-5-yl]amino]methyl]-, rel-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 344576-29-0
CMF C18 H24 N2 O

Relative stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 344576-32-5 HCAPLUS
CN 1,3-Benzenedimethanamine, N-[(3aR,4S,5R,7S,7aR)-octahydro-4,7-methano-1H-inden-5-yl]-, rel-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 344576-31-4
CMF C18 H26 N2

Relative stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 344576-34-7 HCAPLUS
CN Benzenecarboximidamide, 3-[[[(3aR,4S,5R,7S,7aR)-octahydro-4,7-methano-1H-inden-5-yl]amino]methyl]-, rel-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 344576-33-6
CMF C18 H25 N3

Relative stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 344576-35-8 HCAPLUS
CN 4,7-Methano-1H-inden-5-amine, octahydro-N-[(3-nitrophenyl)methyl]-, monohydrochloride, (3aR,4S,5R,7S,7aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 344576-37-0 HCAPLUS
CN 4,7-Methano-1H-inden-5-amine, N-[(3-aminophenyl)methyl]octahydro-, (3aR,4S,5R,7S,7aR)-rel-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 344576-36-9
CMF C17 H24 N2

Relative stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 344576-38-1 HCAPLUS
CN 4,7-Methano-1H-inden-5-amine, octahydro-N-[(3-methoxyphenyl)methyl]-N-methyl-, hydrochloride, (3aR,4S,5R,7S,7aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 344576-40-5 HCAPLUS
CN 4,7-Methano-1H-inden-5-aminium, octahydro-N-[(3-methoxyphenyl)methyl]-N,N-dimethyl-, (3aR,4S,5R,7S,7aR)-rel-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 344576-39-2
CMF C20 H30 N O

Relative stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2



RN 344576-41-6 HCAPLUS
CN 4,7-Methano-1H-inden-5-amine, N-[(3-fluorophenyl)methyl]octahydro-, hydrochloride, (3aR,4R,5S,7R,7aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 344576-42-7 HCAPLUS
CN 4,7-Methano-1H-inden-5-amine, octahydro-N-[[2-(trifluoromethyl)phenyl]methyl]-, hydrochloride, (3aR,4S,5R,7S,7aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 344576-43-8 HCAPLUS
CN 4,7-Methano-1H-inden-5-amine, N-[[3-(dimethylamino)phenyl]methyl]octahydro-, monohydrochloride, (3aR,4S,5R,7S,7aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 344576-44-9 HCAPLUS
CN 4,7-Methano-1H-inden-5-amine, octahydro-N-[2-(3-methoxyphenyl)ethyl]-, hydrochloride, (3aR,4S,5R,7S,7aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 344576-45-0 HCAPLUS
CN 4,7-Methano-1H-inden-5-amine, octahydro-N-[3-(3-methoxyphenyl)propyl]-, hydrochloride, (3aR,4S,5R,7S,7aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



HCl

RN 344576-46-1 HCAPLUS
CN 1,4-Methanonaphthalen-2-amine, decahydro-N-[(3-methoxyphenyl)methyl]-, hydrochloride, (1R,2S,4R,4aS,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 344576-47-2 HCAPLUS
CN 4,7-Methano-1H-inden-5-amine, octahydro-N-[(4-methoxyphenyl)methyl]-, hydrochloride, (3aR,4S,5R,7S,7aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 344576-48-3 HCAPLUS
CN 4,7-Methano-1H-inden-5-amine, octahydro-N-[(2-methoxyphenyl)methyl]-, hydrochloride, (3aR,4S,5R,7S,7aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 344576-49-4 HCAPLUS
CN 4,7-Methano-1H-inden-5-amine, N-[(2,5-dimethoxyphenyl)methyl]octahydro-, hydrochloride, (3aR,4S,5R,7S,7aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 344576-50-7 HCAPLUS
CN 1,3-Benzodioxole-5-methanamine, N-[(3aR,4S,5R,7S,7aR)-octahydro-4,7-methano-1H-inden-5-yl]-, hydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



HCl

RN 344576-51-8 HCAPLUS
CN 4,7-Methano-1H-inden-5-amine, N-[(3,4-dimethoxyphenyl)methyl]octahydro-, (3aR,4S,5R,7S,7aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 344576-52-9 HCAPLUS
CN 4,7-Methano-1H-inden-5-amine, N-[(2,4-dimethoxyphenyl)methyl]octahydro-, hydrochloride, (3aR,4S,5R,7S,7aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 344576-53-0 HCAPLUS
CN 4,7-Methano-1H-inden-5-amine, N-[(4-fluoro-3-methoxyphenyl)methyl]octahydro-, hydrochloride, (3aR,4S,5R,7S,7aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 344576-54-1 HCAPLUS
CN Phenol, 3-[[[(3aR,4S,5R,7S,7aR)-octahydro-4,7-methano-1H-inden-5-yl]amino]methyl]-, hydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 344576-56-3 HCAPLUS
CN 4,7-Methano-1H-inden-5-amine, octahydro-N-[[3-(trifluoromethoxy)phenyl]methyl]-, (3aR,4S,5R,7S,7aR)-rel-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 344576-55-2
CMF C18 H22 F3 N O

Relative stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 344576-57-4 HCAPLUS
CN 4,7-Methano-1H-inden-5-amine, N-[(3-ethoxyphenyl)methyl]octahydro-, hydrochloride, (3aR,4S,5R,7S,7aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 344576-59-6 HCAPLUS
CN 4,7-Methano-1H-inden-5-amine, octahydro-N-[[3-(1,1,2,2-tetrafluoroethoxy)phenyl]methyl]-, (3aR,4S,5R,7S,7aR)-rel-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 344576-58-5
CMF C19 H23 F4 N O

Relative stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 344576-60-9 HCAPLUS
CN 4,7-Methano-1H-inden-5-amine, octahydro-N-[[3-(1-methylethoxy)phenyl]methyl]-, hydrochloride, (3aR,4S,5R,7S,7aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 344576-62-1 HCAPLUS
CN 4,7-Methano-1H-inden-5-amine, N-[(3-ethoxy-4-methoxyphenyl)methyl]octahydro-, (3aR,4S,5R,7S,7aR)-rel-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 344576-61-0
CMF C20 H29 N O2

Relative stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 344576-63-2 HCAPLUS
CN 4,7-Methano-1H-inden-5-amine, octahydro-N-[(3-methylphenyl)methyl]-, hydrochloride, (3aR,4S,5R,7S,7aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 344576-64-3 HCAPLUS
CN 4,7-Methano-1H-inden-5-amine, octahydro-N-[[3-(trifluoromethyl)phenyl]methyl]-, hydrochloride, (3aR,4S,5R,7S,7aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 344576-65-4 HCAPLUS
CN Benzoic acid, 2,6-dimethoxy-3-[[[(3aR,4S,5R,7S,7aR)-octahydro-4,7-methano-1H-inden-5-yl]amino]methyl]-, methyl ester, hydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 344576-66-5 HCAPLUS
CN 4,7-Methano-1H-inden-5-amine, octahydro-N-[(3,4,5-trifluorophenyl)methyl]-, hydrochloride, (3aR,4S,5R,7S,7aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 344576-67-6 HCAPLUS
CN Benzenesulfonamide, 2-chloro-5-[[[(3aR,4S,5R,7S,7aR)-octahydro-4,7-methano-1H-inden-5-yl]amino]methyl]-, monohydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 344576-68-7 HCAPLUS
CN 4,7-Methano-1H-inden-5-amine, N-[[3-(cyclopentyloxy)phenyl]methyl]octahydro-, hydrochloride, (3aR,4S,5R,7S,7aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 344576-69-8 HCAPLUS
CN 4,7-Methano-1H-inden-5-amine, N-[[3-(cyclobutyloxy)phenyl]methyl]octahydro-, hydrochloride, (3aR,4S,5R,7S,7aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 344576-70-1 HCAPLUS
CN 4,7-Methano-1H-inden-5-amine, N-[[3-(cyclohexyloxy)phenyl]methyl]octahydro-, hydrochloride, (3aR,4S,5R,7S,7aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



HCl

RN 344576-71-2 HCAPLUS
CN 4,7-Methano-1H-inden-5-amine, N-[(3,4-difluorophenyl)methyl]octahydro-, hydrochloride, (3aR,4S,5R,7S,7aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 344576-72-3 HCAPLUS
CN 4,7-Methano-1H-inden-5-amine, N-[(3,5-dimethoxyphenyl)methyl]octahydro-, hydrochloride, (3aR,4S,5R,7S,7aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 344576-73-4 HCAPLUS
CN 4,7-Methano-1H-inden-5-amine, N-[(3-ethylphenyl)methyl]octahydro-, hydrochloride, (3aR,4S,5R,7S,7aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 344576-74-5 HCAPLUS
CN 4,7-Methano-1H-inden-5-amine, N-[(2-fluorophenyl)methyl]octahydro-, hydrochloride, (3aR,4S,5R,7S,7aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 344576-75-6 HCAPLUS
CN 4,7-Methano-1H-inden-5-amine, octahydro-N-[[2-[(trifluoromethyl)thio]phenyl]methyl]-, hydrochloride, (3aR,4S,5R,7S,7aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 344576-76-7 HCAPLUS
CN 4,7-Methano-1H-inden-5-amine, octahydro-N-[[4-(trifluoromethoxy)phenyl]methyl]-, hydrochloride, (3aR,4S,5R,7S,7aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 344576-77-8 HCAPLUS
CN 4,7-Methano-1H-inden-5-amine, octahydro-N-[[3-(methylthio)phenyl]methyl]-, hydrochloride, (3aR,4S,5R,7S,7aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 344576-78-9 HCAPLUS
CN 4,7-Methano-1H-inden-5-amine, octahydro-N-[[4-(trifluoromethyl)phenyl]methyl]-, hydrochloride, (3aR,4S,5R,7S,7aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 344576-80-3 HCAPLUS
CN Phenol, 2-methoxy-4-nitro-6-[[[(3aR,4S,5R,7S,7aR)-octahydro-4,7-methano-1H-inden-5-yl]amino]methyl]-, rel-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 344576-79-0
CMF C18 H24 N2 O4

Relative stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 344576-82-5 HCAPLUS
CN 4,7-Methano-1H-inden-5-amine, N-[[3-(3,4-dichlorophenoxy)phenyl]methyl]oct
ahydro-, (3aR,4S,5R,7S,7aR)-rel-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 344576-81-4
CMF C23 H25 Cl2 N O

Relative stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 344576-83-6 HCAPLUS
CN 4,7-Methano-1H-inden-5-amine, N-[1-(3-chlorophenyl)ethyl]octahydro-, hydrochloride, (3aR,4S,5R,7S,7aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 344576-84-7 HCAPLUS
CN 4,7-Methano-1H-inden-5-amine, octahydro-N-[1-(3-methylphenyl)ethyl]-, hydrochloride, (3aR,4S,5R,7S,7aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 344576-85-8 HCAPLUS
CN 4,7-Methano-1H-inden-5-amine, octahydro-N-[1-[4-methoxy-3-(methylsulfonyl)phenyl]ethyl]-, hydrochloride, (3aR,4S,5R,7S,7aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 344576-86-9 HCAPLUS
CN Benzenesulfonamide, 2-chloro-5-[1-[[(3aR,4S,5R,7S,7aR)-octahydro-4,7-methano-1H-inden-5-yl]amino]ethyl]-, monohydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 344576-87-0 HCAPLUS
CN 4,7-Methano-1H-inden-5-amine, N-[1-[4-chloro-3-(methylsulfonyl)phenyl]ethyl]octahydro-, hydrochloride, (3aR,4S,5R,7S,7aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 344576-88-1 HCAPLUS
CN 4,7-Methano-1H-inden-5-amine, octahydro-N-[[3-(methylsulfonyl)phenyl]methyl]-, hydrochloride, (3aR,4S,5R,7S,7aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 344576-94-9 HCAPLUS
CN 4,7-Methano-1H-inden-6-amine, N-[(3-fluorophenyl)methyl]-3a,4,5,6,7,7a-hexahydro-, (3aR,4R,6S,7R,7aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 344576-95-0 HCAPLUS
CN 4,7-Methano-1H-inden-6-amine, 3a,4,5,6,7,7a-hexahydro-N-[(3-methoxyphenyl)methyl]-, (3aR,4R,6S,7R,7aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 344577-06-6 HCAPLUS
CN Benzoic acid, 3-[[[(3aR,4S,5R,7S,7aR)-octahydro-4,7-methano-1H-inden-5-yl]amino]methyl]-, ethyl ester, hydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 344577-07-7 HCAPLUS
CN 4,7-Methano-1H-inden-5-amine, N-[(3-chlorophenyl)methyl]octahydro-, (3aR,4S,5R,7S,7aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 344577-08-8 HCAPLUS
CN 4,7-Methano-1H-inden-5-amine, N-[(3-fluorophenyl)methyl]octahydro-, (3aR,4S,5R,7S,7aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 344577-09-9 HCAPLUS
CN 1,3-Benzodioxole-5-methanamine, N-[(3aR,4S,5R,7S,7aR)-octahydro-4,7-methano-1H-inden-5-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 344577-10-2 HCAPLUS
CN 4,7-Methano-1H-inden-5-amine, octahydro-N-[(3-methoxyphenyl)methyl]-, (3aR,4S,5R,7S,7aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 344577-11-3 HCAPLUS
CN 4,7-Methano-1H-inden-5-amine, octahydro-N-[(3-methoxyphenyl)methyl]-, (3aS,4R,5S,7R,7aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 344577-12-4 HCAPLUS
CN 4,7-Methano-1H-inden-5-amine, octahydro-N-[(3-methoxyphenyl)methyl]-, (3aR,4S,5R,7S,7aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 344577-13-5 HCAPLUS
CN 4,7-Methano-1H-inden-5-amine, octahydro-N-[1-(3-methoxyphenyl)ethyl]-, (3aR,4S,5R,7S,7aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 344577-14-6 HCAPLUS
CN 1,4-Methanonaphthalen-2-amine, decahydro-N-[(3-methoxyphenyl)methyl]-, (1R,2S,4R,4aS,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 344577-15-7 HCAPLUS
CN 4,7-Methano-1H-inden-5-amine, N-[(3,5-difluorophenyl)methyl]octahydro-, (3aR,4S,5R,7S,7aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 344577-16-8 HCAPLUS
CN 4,7-Methano-1H-inden-5-amine, N-[(3-fluorophenyl)methyl]octahydro-, (3aR,4R,5S,7R,7aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 344577-17-9 HCAPLUS
CN 4,7-Methano-1H-inden-5-amine, octahydro-N-[(3-methoxyphenyl)methyl]-, (3aR,4R,5S,7R,7aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT **344577-01-1P 344577-02-2P 344577-03-3P**
344577-04-4P 344577-19-1P
RL: RCT (Reactant); **SPN (Synthetic preparation); PREP (Preparation)**
(prepn. of substituted norbornylamino derivs. for use as a antihypertensive agent or a diagnostic reagent)
RN 344577-01-1 HCAPLUS
CN Benzenecarboximidic acid, 3-[[[(3aR,4S,5R,7S,7aR)-octahydro-4,7-methano-1H-inden-5-yl]amino]methyl]-, ethyl ester, dihydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



2 HCl

RN 344577-02-2 HCAPLUS
CN Benzamide, 3-(dimethylamino)-N-[(3aR,4S,5R,7S,7aR)-octahydro-4,7-methano-1H-inden-5-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 344577-03-3 HCAPLUS
CN Benzeneacetamide, 3-methoxy-N-[(3aR,4S,5R,7S,7aR)-octahydro-4,7-methano-1H-inden-5-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 344577-04-4 HCAPLUS
CN Benzenepropanamide, 3-methoxy-N-[(3aR,4S,5R,7S,7aR)-octahydro-4,7-methano-1H-inden-5-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 344577-19-1 HCAPLUS
CN Benzonitrile, 3-[[[(3aR,4S,5R,7S,7aR)-octahydro-4,7-methano-1H-inden-5-yl]amino]methyl]-, rel-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 344577-18-0
CMF C18 H22 N2

Relative stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



L32 ANSWER 2 OF 15 HCAPLUS COPYRIGHT 2002 ACS
AN 2000:824211 HCAPLUS
DN 134:4764
TI Preparation of 3-(benzoylamino)propionic acid derivatives as glucagon antagonists/inverse agonists
IN Ling, Anthony; Plewe, Michael Bruno; Truesdale, Larry Kenneth; Lau, Jesper; Madsen, Peter; Sams, Christian; Behrens, Carsten; Vagner, Josef; Christensen, Inge Thoger; Lundt, Behrend Frederik; Sidelmann, Ulla Grove; Thogersen, Henning
PA Novo Nordisk A/S, Den.; Agouron Pharmaceuticals, Inc.
SO PCT Int. Appl., 564 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM C07C237-32
ICS C07C243-24; C07C271-40; C07C275-28; C07D209-48; C07D257-04; C07D333-04; A61K031-15; A61K031-165; A61K031-17; A61K031-33; A61P003-04; A61P003-10
CC 25-19 (Benzene, Its Derivatives, and Condensed Benzenoid Compounds)
Section cross-reference(s): 1, 63
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000069810	A1	20001123	WO 2000-DK264	20000516

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE,

SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW,
AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRAI DK 1999-684 A 19990517
DK 2000-478 A 20000321
OS MARPAT 134:4764
GI



I



II



III

AB The title compds. [I; V = CO2R2, CONR2R3, CONR2OR3, etc. (wherein R2, R3 = H, alkyl); A = (CH2)n(CR8R9)bNR7, (CR8R9)b(CH2)nNR7, (CR8R9)b(CH2)n, etc. (b = 0-1; n = 0-3; R7 = H, alkyl, (cycloalkyl)alkyl; R8, R9 = H, alkyl); Y = CO, SO2, O, a bond; Z = (un)substituted phenylene, divalent radical derived from 5-6 membered heteroarom. ring contg. 1-2 heteroatoms selected from N, O and S; or AYZ together = II; R1 = H, alkyl; X = CO(CR13R14)r(CH2)s, SO2(CR13R14)r(CH2)s, CO2(CR13R14)r(CH2)s, etc. (r = 0-1; s = 0-3; R13, R14 = H, alkyl); D = (un)substituted Ph, pyridyl, cyclopropyl, etc.; E = (un)substituted quinolinyl, 2,5-dioxopiperidinyl, biphenylalkyl, etc.] which act to antagonize the action of the glucagon hormone on the glucagon receptor (data given), and therefore may be suitable for the treatment and/or prevention of any glucagon-mediated conditions and diseases such as hyperglycemia, Type 1 diabetes, Type 2 diabetes and obesity, were prepd. and formulated. E.g., a multi-step solid phase synthesis of III was given. Compds. I are effective at 0.05-10 mg/kg/day.

ST benzoylaminopropionic acid prepn formulation glucagon receptor antidiabetic antiobesity

IT Antidiabetic agents
Antiobesity agents
(prepn. of 3-(benzoylamino)propionic acid derivs. as glucagon antagonists/inverse agonists)

IT Glucagon receptors
RL: BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study)
(prepn. of 3-(benzoylamino)propionic acid derivs. as glucagon antagonists/inverse agonists)

IT 307983-31-9P 307983-34-2P 307983-40-0P 307985-34-8P 307985-49-5P
307985-95-1P
RL: BAC (Biological activity or effector, except adverse); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 3-(benzoylamino)propionic acid derivs. as glucagon antagonists/inverse agonists)

IT 307982-44-1P 307982-45-2P 307982-46-3P 307982-47-4P 307982-48-5P
307982-49-6P 307982-50-9P 307982-51-0P 307982-52-1P 307982-53-2P
307982-54-3P 307982-55-4P 307982-56-5P 307982-57-6P 307982-58-7P
307982-59-8P 307982-60-1P 307982-61-2P 307982-62-3P 307982-63-4P
307982-64-5P 307982-65-6P 307982-66-7P 307982-67-8P 307982-68-9P
307982-69-0P 307982-70-3P 307982-71-4P 307982-72-5P 307982-74-7P
307982-75-8P 307982-76-9P 307982-77-0P 307982-78-1P 307982-79-2P
307982-80-5P 307982-81-6P 307982-82-7P 307982-83-8P 307982-84-9P
307982-85-0P 307982-86-1P 307982-87-2P 307982-88-3P 307982-89-4P
307982-90-7P 307982-91-8P 307982-92-9P 307982-93-0P 307982-94-1P
307982-95-2P 307982-96-3P 307982-97-4P 307982-98-5P 307982-99-6P
307983-00-2P 307983-01-3P 307983-02-4P 307983-03-5P 307983-04-6P
307983-05-7P 307983-06-8P 307983-07-9P 307983-08-0P 307983-09-1P
307983-10-4P 307983-11-5P 307983-12-6P 307983-13-7P 307983-14-8P
307983-15-9P 307983-16-0P 307983-17-1P 307983-18-2P 307983-19-3P
307983-20-6P 307983-21-7P 307983-22-8P 307983-23-9P 307983-24-0P
307983-25-1P 307983-26-2P 307983-27-3P 307983-28-4P 307983-29-5P
307983-30-8P 307983-32-0P 307983-33-1P 307983-36-4P 307983-38-6P
307983-42-2P 307983-44-4P 307983-46-6P 307983-48-8P 307983-50-2P
307983-51-3P 307983-52-4P 307983-53-5P 307983-54-6P 307983-55-7P
307983-56-8P 307983-57-9P 307983-58-0P 307983-59-1P 307983-60-4P
307983-61-5P 307983-84-2P 307983-85-3P 307983-86-4P 307983-87-5P
307984-00-5P 307984-01-6P 307984-02-7P 307984-03-8P 307984-04-9P
307984-05-0P 307984-18-5P 307984-19-6P 307984-20-9P 307984-21-0P
307984-22-1P 307984-23-2P 307984-24-3P 307984-25-4P 307984-84-5P
307984-85-6P 307984-86-7P 307984-87-8P 307984-88-9P 307984-89-0P
307984-90-3P 307984-91-4P 307984-92-5P 307984-93-6P 307984-94-7P
307984-95-8P 307984-96-9P 307984-97-0P 307984-98-1P 307984-99-2P
307985-00-8P 307985-01-9P 307985-02-0P 307985-03-1P 307985-04-2P
307985-05-3P 307985-06-4P 307985-07-5P 307985-08-6P 307985-09-7P
307985-10-0P 307985-11-1P 307985-12-2P 307985-13-3P 307985-14-4P
307985-15-5P 307985-16-6P 307985-17-7P 307985-18-8P 307985-19-9P
307985-20-2P 307985-21-3P 307985-22-4P 307985-23-5P 307985-24-6P
307985-25-7P 307985-26-8P 307985-27-9P 307985-28-0P 307985-29-1P
307985-30-4P 307985-31-5P 307985-32-6P 307985-33-7P 307985-36-0P
307985-37-1P 307985-38-2P 307985-39-3P 307985-40-6P 307985-41-7P
307985-42-8P 307985-43-9P 307985-44-0P 307985-45-1P 307985-46-2P
307985-47-3P 307985-48-4P 307985-50-8P 307985-51-9P 307985-52-0P
307985-53-1P 307985-54-2P 307985-55-3P 307985-56-4P 307985-57-5P
307985-58-6P 307985-59-7P 307985-60-0P 307985-61-1P 307985-62-2P
307985-63-3P 307985-64-4P 307985-65-5P 307985-66-6P 307985-67-7P
307985-68-8P 307985-69-9P 307985-70-2P 307985-71-3P 307985-72-4P
307985-73-5P 307985-74-6P 307985-75-7P 307985-76-8P 307985-77-9P
307985-78-0P 307985-79-1P 307985-80-4P 307985-81-5P 307985-82-6P
307985-83-7P 307985-84-8P 307985-85-9P 307985-86-0P 307985-87-1P
307985-88-2P 307985-89-3P 307985-90-6P 307985-91-7P 307985-92-8P
307985-93-9P 307985-94-0P 307985-96-2P 307985-97-3P 307985-98-4P
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic

preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 3-(benzoylamino)propionic acid derivs. as glucagon antagonists/inverse agonists)

IT 307985-99-5P 307986-00-1P 307986-01-2P 307986-02-3P 307986-03-4P
307986-04-5P 307986-05-6P 307986-06-7P 307986-07-8P 307986-08-9P
307986-09-0P 307986-10-3P 307986-11-4P 307986-12-5P 307986-13-6P
307986-14-7P 307986-15-8P 307986-16-9P 307986-17-0P 307986-18-1P
307986-19-2P 307986-20-5P 307986-21-6P 307986-22-7P 307986-23-8P
307986-24-9P 307986-25-0P 307986-26-1P 307986-27-2P 307986-28-3P
307986-29-4P 307986-30-7P 307986-31-8P 307986-32-9P 307986-33-0P
307986-34-1P 307986-35-2P 307986-36-3P 307986-37-4P 307986-39-6P
307986-40-9P 307986-41-0P 307986-42-1P 307986-43-2P 307986-44-3P
307986-45-4P 307986-46-5P 307986-47-6P 307986-48-7P 307986-49-8P
307986-50-1P 307986-51-2P 307986-52-3P 307986-53-4P 307986-54-5P
307986-55-6P 307986-56-7P 307986-57-8P 307986-58-9P 307986-59-0P
307986-60-3P 307986-61-4P 307986-62-5P 307986-64-7P 307986-65-8P
307986-66-9P 307986-67-0P 307986-68-1P 307986-69-2P 307986-70-5P
307986-71-6P 307986-72-7P 307986-73-8P 307986-74-9P 307986-75-0P
307986-76-1P 307986-77-2P 307986-78-3P **307986-79-4P**
307986-80-7P 307986-81-8P 307986-82-9P 307986-83-0P 307986-84-1P
307986-85-2P 307986-86-3P 307986-87-4P 307986-88-5P 307986-89-6P
307986-90-9P 307986-91-0P 307986-92-1P 307986-93-2P 307986-94-3P
307986-95-4P 307986-96-5P 307986-97-6P 307986-98-7P 307986-99-8P
307987-00-4P 307987-01-5P 307987-02-6P 307987-03-7P 307987-04-8P
307987-05-9P 307987-06-0P 307987-07-1P 307987-08-2P 307987-09-3P
307987-11-7P 307987-13-9P 307987-14-0P 307987-15-1P 307987-16-2P
307987-17-3P 307987-18-4P 307987-19-5P 307987-20-8P 307987-21-9P
307987-22-0P 307987-23-1P 307987-24-2P 307987-25-3P 307987-26-4P
307987-27-5P 307987-28-6P 307987-29-7P 307987-30-0P 307987-31-1P
307987-32-2P 307987-33-3P 307987-34-4P 307987-35-5P 307987-36-6P
307987-37-7P 307987-38-8P 307987-39-9P 307987-40-2P 307987-41-3P
307987-42-4P 307987-43-5P 307987-44-6P 307987-45-7P 307987-46-8P
307987-47-9P 307987-48-0P 307987-49-1P 307987-50-4P 307987-51-5P
307987-52-6P 307987-53-7P 307987-54-8P 307987-55-9P 307987-56-0P
307987-57-1P 307987-58-2P 307987-59-3P 307987-60-6P 307987-61-7P
307987-62-8P 307987-63-9P 307987-64-0P 307987-65-1P 307987-66-2P
307987-67-3P 307987-68-4P 307987-69-5P 307987-70-8P 307987-71-9P
307987-72-0P 307987-73-1P 307987-74-2P 307987-75-3P 307987-76-4P
307987-77-5P 307987-78-6P 307987-79-7P 307987-80-0P 307987-81-1P
307987-82-2P 307987-83-3P 307987-84-4P 307987-85-5P 307987-86-6P
307987-87-7P 307987-88-8P 307987-89-9P 307987-90-2P 307987-91-3P
307987-92-4P 307987-93-5P 307987-94-6P 307987-95-7P 307987-96-8P
307987-97-9P 307987-98-0P 307987-99-1P 307988-00-7P 307988-01-8P
307988-02-9P 307988-03-0P 307988-04-1P 307988-05-2P 307988-06-3P
307988-07-4P 307988-08-5P 307988-09-6P 307988-10-9P 307988-11-0P
307988-12-1P 307988-13-2P 307988-14-3P 307988-15-4P 307988-16-5P
307988-17-6P 307988-18-7P 307988-19-8P 307988-20-1P 307988-21-2P
307988-22-3P 307988-23-4P 307988-24-5P 307988-25-6P 307988-26-7P
307988-27-8P 307988-28-9P 307988-29-0P 307988-30-3P 307988-31-4P
307988-32-5P 307988-33-6P 307988-34-7P 307988-35-8P 307988-36-9P
307988-37-0P

RL: BAC (Biological activity or effector, except adverse); **SPN (Synthetic preparation)**; THU (Therapeutic use); BIOL (Biological study); **PREP (Preparation)**; USES (Uses)
(prepn. of 3-(benzoylamino)propionic acid derivs. as glucagon antagonists/inverse agonists)

IT 307988-38-1P 307988-39-2P 307988-40-5P 307988-41-6P 307988-42-7P
307988-43-8P 307988-44-9P 307988-45-0P 307988-46-1P 307988-47-2P
307988-48-3P 307988-49-4P 307988-50-7P 307988-51-8P 307988-52-9P

307988-53-0P 307988-54-1P 307988-55-2P 307988-56-3P 307988-57-4P
307988-58-5P 307988-59-6P 307988-60-9P 307988-61-0P 307988-62-1P
307988-63-2P 307988-64-3P 307988-65-4P 307988-66-5P 307988-67-6P
307988-68-7P 307988-69-8P 307988-70-1P 307988-71-2P 307988-72-3P
307988-73-4P 307988-74-5P 307988-75-6P 307988-76-7P 307988-77-8P
307988-78-9P 307988-79-0P 307988-80-3P 307988-81-4P 307988-82-5P
307988-83-6P 307988-84-7P 307988-85-8P 307988-86-9P 307988-87-0P
307988-88-1P 307988-89-2P 307988-90-5P 307988-91-6P 307988-92-7P
307988-93-8P 307988-94-9P 307988-95-0P 307990-61-0P 307990-62-1P
307990-63-2P 307990-64-3P 307990-65-4P 308084-88-0P
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 3-(benzoylamino)propionic acid derivs. as glucagon antagonists/inverse agonists)

IT 307983-62-6 307983-63-7 307983-64-8 307983-65-9 307983-66-0
307983-67-1 307983-69-3 307983-70-6 307983-71-7 307983-72-8
307983-73-9 307983-74-0 307983-75-1 307983-76-2 307983-77-3
307983-78-4 307983-79-5 307983-80-8 307983-81-9 307983-82-0
307983-83-1 307983-88-6 307983-89-7 307983-90-0 307983-91-1
307983-92-2 307983-93-3 307983-94-4 307983-95-5 307983-96-6
307983-97-7 307983-98-8 307983-99-9 307984-06-1 307984-07-2
307984-08-3 307984-09-4 307984-10-7 307984-11-8 307984-12-9
307984-13-0 307984-14-1 307984-15-2 307984-16-3 307984-17-4
307984-26-5 307984-27-6 307984-28-7 307984-29-8 307984-30-1
307984-31-2 307984-32-3 307984-33-4 307984-34-5 307984-35-6
307984-36-7 307984-37-8 307984-38-9 307984-39-0 307984-40-3
307984-41-4 307984-43-6 307984-45-8 307984-47-0 307984-49-2
307984-51-6 307984-53-8 307984-55-0 307984-57-2 307984-58-3
307984-59-4 307984-60-7 307984-61-8 307984-62-9 307984-63-0
307984-64-1 307984-65-2 307984-66-3 307984-67-4 307984-68-5
307984-69-6 307984-70-9 307984-71-0 307984-72-1 307984-73-2
307984-74-3 307984-75-4 307984-76-5 307984-77-6 307984-78-7
307984-79-8 307984-80-1 307984-81-2 307984-82-3 307984-83-4
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(prepn. of 3-(benzoylamino)propionic acid derivs. as glucagon antagonists/inverse agonists)

IT 62-53-3, Aniline, reactions 75-33-2, 2-Propanethiol 88-30-2, 1-Nitro-4-hydroxy-2-trifluoromethylbenzene 89-40-7, 4-Nitrophthalimide 92-68-2, 4-Cyclohexylcyclohexanone 92-69-3, Biphenyl-4-ol 95-55-6, 2-Aminophenol 97-62-1, Ethyl isobutyrate 98-53-3, 4-tert-Butylcyclohexanone 98-74-8, 4-Nitrophenylsulfonyl chloride 99-99-0, 4-Nitrotoluene 100-02-7, 4-Nitrophenol, reactions 103-71-9, Phenyl isocyanate, reactions 104-13-2, 4-Butylaniline 104-75-6, 2-Ethylhexylamine 108-67-8, 1,3,5-Trimethylbenzene, reactions 108-94-1, Cyclohexanone, reactions 108-95-2, Phenol, reactions 109-65-9 109-73-9, 1-Butylamine, reactions 122-04-3, 4-Nitrobenzoyl chloride 123-05-7, 2-Ethylhexanal 328-74-5, 3,5-Bis(trifluoromethyl)aniline 461-82-5, 4-Trifluoromethoxyaniline 586-89-0, 4-Acetylbenzoic acid 619-23-8, m-Nitrobenzyl chloride 619-24-9 619-66-9, 4-Formylbenzoic acid 626-04-0, 1,3-Benzenedithiol 634-91-3, 3,4,5-Trichloroaniline 765-30-0, Cyclopropylamine 773-64-8, Mesitylenesulfonyl chloride 924-73-2, 3-Aminopropionic acid ethyl ester 1571-08-0, Methyl 4-formylbenzoate 1572-10-7, 5-Amino-3-phenylpyrazole 1744-22-5, 2-Amino-6-(trifluoromethoxy)benzothiazole 1918-79-2, 5-Methylthiophene-2-carboxylic acid 2144-37-8, Methyl 5-chloromethyl-2-furanoate 2417-72-3, Methyl 4-(bromomethyl)benzoate 2516-33-8, Cyclopropylcarbinol 3222-47-7, 6-Methylnicotinic acid 3290-06-0, 3,5-Dichlorobenzyl chloride 3300-51-4, 4-

Trifluoromethylbenzylamine 3958-57-4, 3-Nitrobenzyl bromide 3963-62-0, 2,2-Diphenylethylamine 4138-35-6, .beta.-Alanine methyl ester 4244-84-2, .beta.-Alanine ethyl ester hydrochloride 4418-61-5, 5-Aminotetrazole 4548-45-2, 5-Nitro-2-chloropyridine 4746-97-8, 1,4-Cyclohexanedione monoethylene ketal 5400-88-4, 4-tert-Butylcyclohexylamine 5458-48-0, 4-Cyclohexylnitrobenzene 5466-84-2, 4-Nitrophthalic anhydride 6232-11-7, Methyl 4-(aminomethyl)benzoate hydrochloride 6232-88-8, 4-Bromomethylbenzoic acid 6287-86-1, Ethyl 4-formylbenzoate 6373-50-8, 4-Cyclohexylaniline 7051-34-5, Bromomethylcyclopropane 10203-08-4, 3,5-Dichlorobenzaldehyde 10576-12-2, Ethyl acetohydroxamate 13736-78-2 14114-05-7, Cyclopropyltriphenylphosphonium bromide 16361-24-3, 5-Chlorobenzo[b]thiophene-3-carboxylic acid 16588-74-2, 3,5-Bis(trifluoromethyl)phenyl isocyanate 19438-61-0, 4-Methylphthalic anhydride 20503-40-6 23981-90-0, 2-(5-Methoxynaphthalen-2-yl)propionic acid 27489-62-9, trans-4-Hydroxycyclohexylamine 28479-19-8, 3-Methylthiophenyl isocyanate 31602-63-8, 5-Aminomethyltetrazole 34893-92-0, 3,5-Dichlorophenyl isocyanate 35037-73-1, 4-Trifluoromethoxyphenyl isocyanate 35661-51-9 36823-88-8, 4-Trifluoromethoxybenzoyl chloride 39827-11-7, Benzo[b]thiophene-2-carbonyl chloride 39989-43-0, 3,5-Dichlorobenzylamine 50850-93-6, Ethyl 2-aminobenzothiazole-6-carboxylate 51859-12-2, 3,5-Bis(methylsulfonyl)phenylamine 63968-85-4 66176-39-4, 4-Bromomethylphenylsulfonyl chloride 67808-64-4, Methyl 5-formylthiophene-2-carboxylate 81172-89-6 89586-07-2 89895-55-6, Nipecotic acid methyl ester hydrochloride 148437-99-4 171243-30-4, 3-Fluoro-5-trifluoromethylbenzoyl chloride 175278-01-0 302912-19-2 307976-49-4 307983-14-8D, resin bound 307983-29-5D, resin bound 307985-07-5D, resin bound 307986-36-3D, resin bound 307986-84-1D, resin bound 307986-89-6D, resin bound 307986-98-7D, resin bound 307987-11-7D, resin bound 307987-13-9D, resin bound 307987-14-0D, resin bound 307987-29-7D, resin bound 307990-33-6 307990-34-7 307990-35-8 307990-36-9 307990-37-0 307990-38-1 307990-39-2 307990-40-5 307990-41-6 307990-42-7 307990-43-8 307990-44-9 307990-45-0 307990-46-1 307990-47-2 307990-48-3 307990-49-4D, resin bound 307990-50-7 307990-51-8 307990-52-9 307990-53-0 307990-54-1 307990-55-2 307990-56-3 307990-57-4 307990-58-5D, resin bound 307990-59-6 307990-60-9D, resin bound

RL: RCT (Reactant)

(prepn. of 3-(benzoylamino)propionic acid derivs. as glucagon antagonists/inverse agonists)

IT 1747-75-7P 2388-69-4P 5345-27-7P, 3-Methylsulfonylbenzoic acid 21315-03-7P 21871-44-3P 25194-67-6P, 5-Amino-2-phenoxypyridine 28022-30-2P 28022-31-3P 28222-02-8P, 5-Nitro-2-phenoxypyridine 35737-10-1DP, resin bound 36016-40-7P 38202-27-6P 43114-43-8P 54395-37-8P 58683-63-9P 65141-19-7P 66473-14-1P, N-Butyl-4-nitrobenzenesulfonamide 68930-97-2P 69746-32-3P 69790-73-4P 83051-21-2P 85002-74-0P, 1-Cyclopropylmethoxy-4-nitrobenzene 90222-83-6P 114934-51-9P 115737-91-2P 122828-48-2P, 4-Cyclopropylmethoxyaniline 175277-18-6P 175278-17-8P, 2-Bromo-4-trifluoromethoxyaniline 220798-39-0P 257625-08-4P, 1-Methylsulfanyl-2-trifluoromethoxybenzene 261924-46-3P 261925-02-4P 307972-69-6P 307982-44-1DP, resin bound 307986-51-2DP, resin bound 307986-76-1DP, resin bound 307988-96-1DP, resin bound 307988-97-2DP, resin bound 307988-98-3P 307988-99-4P 307989-00-0P 307989-01-1P 307989-02-2P 307989-03-3P 307989-04-4P 307989-05-5P 307989-06-6P 307989-07-7P 307989-08-8P 307989-09-9P 307989-10-2P 307989-11-3P 307989-12-4P 307989-13-5P 307989-14-6P 307989-15-7P 307989-17-9P 307989-19-1P 307989-20-4P 307989-21-5P 307989-22-6P 307989-23-7P 307989-24-8P 307989-26-0P 307989-27-1P 307989-29-3P 307989-30-6P

307989-31-7P 307989-32-8P 307989-33-9P 307989-34-0P 307989-35-1P
307989-36-2P 307989-37-3P 307989-38-4P 307989-39-5P 307989-40-8P
307989-41-9P 307989-42-0P, 5-Nitro-2-trifluoromethoxybenzoic acid methyl ester 307989-43-1P, 5-Amino-2-trifluoromethoxybenzoic acid methyl ester
307989-44-2P 307989-45-3P 307989-46-4P 307989-47-5P 307989-48-6P
307989-49-7P 307989-50-0P 307989-51-1P 307989-52-2P 307989-53-3P
307989-54-4P 307989-55-5P 307989-56-6P 307989-57-7P 307989-58-8P
307989-59-9P 307989-60-2P 307989-61-3P 307989-62-4P 307989-63-5P
307989-64-6P 307989-65-7P 307989-66-8P 307989-67-9P 307989-68-0P
307989-69-1DP, resin bound 307989-70-4DP, resin bound 307989-71-5P
307989-72-6P 307989-73-7P 307989-75-9P 307989-77-1P 307989-78-2P
307989-79-3P 307989-80-6P 307989-81-7P 307989-82-8P 307989-83-9P
307989-84-0P 307989-85-1P 307989-86-2P 307989-87-3P 307989-88-4P
307989-89-5P 307989-90-8P 307989-91-9P 307989-92-0P 307989-93-1P
307989-94-2P 307989-96-4P 307989-97-5P 307989-99-7P 307990-00-7P
307990-01-8P 307990-02-9P 307990-04-1P 307990-05-2P 307990-07-4P
307990-09-6P 307990-11-0P 307990-13-2P 307990-15-4P 307990-16-5P
307990-17-6P 307990-18-7P 307990-19-8P 307990-20-1P 307990-22-3P
307990-23-4P 307990-25-6P 307990-26-7P 307990-27-8P 307990-28-9P
307990-29-0P 307990-30-3P 307990-31-4P 307990-32-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. of 3-(benzoylamino)propionic acid derivs. as glucagon antagonists/inverse agonists)

IT 1829-82-9P, 4-Amino-N-butylbenzenesulfonamide 307989-25-9P
307989-95-3P 307989-98-6P 307990-21-2P 307990-24-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of 3-(benzoylamino)propionic acid derivs. as glucagon antagonists/inverse agonists)

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Beecham Group Limited; EP 0000816 A1 1979 HCAPLUS
(2) Mitsui Chemicals Inc; EP 0847992 A1 1998 HCAPLUS
(3) Novo Nordisk AS; WO 9901423 A1 1999 HCAPLUS

IT **307986-79-4P**
RL: BAC (Biological activity or effector, except adverse); **SPN (Synthetic preparation)**; THU (Therapeutic use); BIOL (Biological study); **PREP (Preparation)**; USES (Uses)
(prepn. of 3-(benzoylamino)propionic acid derivs. as glucagon antagonists/inverse agonists)

RN 307986-79-4 HCAPLUS
CN Benzoic acid, 4-(trifluoromethoxy)-, 2-[[4-[[(2-carboxyethyl)amino]carbonyl]phenyl]methyl]-2-(octahydro-4,7-methano-1H-inden-5-yl)hydrazide (9CI) (CA INDEX NAME)



L32 ANSWER 3 OF 15 HCAPLUS COPYRIGHT 2002 ACS
AN 1998:811714 HCAPLUS
DN 130:138974
TI Unusual photochemical behavior of 5-amino-endo-dicyclopentadien-3-ones
AU Bakkeren, Frank J. A. D.; Schroer, Frank; De Gelder, Rend; Klunder, Antonius J. H.; Zwanenburg, Binne
CS Departments of Organic Chemistry and Inorganic Chemistry, NSR Center for Molecular Structure, Design and Synthesis, University of Nijmegen, Nijmegen, 6525 ED, Neth.
SO Tetrahedron Lett. (1998), 39(51), 9527-9530
CODEN: TELEAY; ISSN: 0040-4039
PB Elsevier Science Ltd.
DT Journal
LA English
CC 22-5 (Physical Organic Chemistry)
Section cross-reference(s): 74
GI



AB Irradn. of 5-amino-substituted endo-tricyclo[5.2.1.06]deca-4,8-dien-3-ones [I; R1,R2 given: H,cyclohexyl; H,benzyl (Bn); (R1R2)= morpholino] did not lead to the anticipated [.pi.2 + .pi.2]-photocyclization, thus not affording bridgehead 1,3-bishomocubyl amines (II; R1,R2 as above). Instead, an unexpected photoredn. of the norbornene C8-C8 double bond was obsd., which based on d-labeling studies involves a photoelectron transfer process. The desired [.pi.2 + .pi.2]-photocyclization could be affected by N-acylation of the amino function in I (R1 = H, R2 = Bn) furnishing 4-amido-substituted 1,3-bishomocubanones (III; R = Me, MeO, Bn, OBn) .
ST aminoendodicyclopentadienone photoreaction mechanism; bishomocubanone prepn

IT Dehydrogenation
(photochem.; photoreactions of amino-substituted endo tricyclodecadienones)
IT Photochemical rearrangement
Photocyclization
(photoreactions of amino-substituted endo tricyclodecadienones)
IT 185542-02-3 185542-06-7 185542-07-8
RL: PEP (Physical, engineering or chemical process); RCT (Reactant); PROC (Process)
(photoreactions of amino-substituted endo tricyclodecadienones)
IT 220006-02-0P 220006-03-1P 220006-04-2P 220006-05-3P
RL: PEP (Physical, engineering or chemical process); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); PROC (Process)
(photoreactions of amino-substituted endo tricyclodecadienones)
IT 202280-04-4P 220006-00-8P 220006-01-9P **220006-06-4P**
220006-07-5P 220006-08-6P 220006-09-7P
RL: **SPN (Synthetic preparation); PREP (Preparation)**
(photoreactions of amino-substituted endo tricyclodecadienones)
RE.CNT 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Anon; Carbocyclic Cage Compounds 1992
(2) Bakkeren, F; Tetrahedron Lett 1996, V37, P8003 HCAPLUS
(3) Bakkeren, F; Tetrahedron Lett 1998, V39, P9531 HCAPLUS
(4) Cantrell, T; Tetrahedron 1971, V27, P1227 HCAPLUS
(5) Davies, W; Science 1964, V144, P862 MEDLINE
(6) Dilling, W; Carbocyclic Cage Compounds 1992, P249 HCAPLUS
(7) Dubowchik, G; Tetrahedron Lett 1996, V37, P6465 HCAPLUS
(8) Gardette, D; Can J Chem 1988, V67, P213
(9) Gelder, R; J Chem Cryst 1997, V27, P677
(10) Gelder, R; J Chem Cryst, submitted for publication
(11) Gerzon, K; J Med Chem 1967, V10, P189 HCAPLUS
(12) Griffin, G; Chem Rev 1989, V89, P997 HCAPLUS
(13) Ikeda, M; Chem Pharm Bull 1981, V29, P2062 HCAPLUS
(14) Klunder, A; Chem Rev 1989, V89, P1035 HCAPLUS
(15) Kruger, H; PhD Thesis, University of Potchefstroom 1996
(16) Lange, J; J Crystallogr Spectrosc Res 1988, V18, P779 HCAPLUS
(17) Marchand, A; Chem Rev 1989, V89, P1011 HCAPLUS
(18) Matlin, A; Chem Pharm Bull 1987, V28, P5087 HCAPLUS
(19) Neumeyer, J; Principles of Medicinal Chemistry 1989, P223
(20) Oliver, D; Drug Res 1991, V41, P549 HCAPLUS
(21) Oliver, D; J Med Chem 1991, V34, P851 HCAPLUS
(22) Rapala, R; J Med Chem 1965, V8, P580 HCAPLUS
(23) Schwab, R; J Am Med Assoc 1969, V208, P1168 MEDLINE
(24) Smits, J; J Crystallogr Spectrosc Res 1988, V18, P797 HCAPLUS
(25) Smits, P; J Crystallogr Spectrosc Res 1988, V18, P785
(26) Tamura, Y; J Org Chem 1975, V40, P2702 HCAPLUS
(27) Tsuda, Y; Chem Pharm Bull 1986, V34, P3614 HCAPLUS
(28) Vogler, B; J Org Chem 1989, V54, P4165 HCAPLUS
(29) Voldeng, A; J Pharm Sci 1968, V57, P1053 HCAPLUS
(30) Winkler, J; Tetrahedron Lett 1986, V27, P5177 HCAPLUS
(31) Zwanenburg, B; Advances in Theoretically Interesting Molecules 1992, V2, P57
(32) Zwanenburg, B; Strain and its Implications in Organic Chemistry 1989, P405 HCAPLUS
IT **220006-06-4P 220006-07-5P 220006-08-6P**
220006-09-7P
RL: **SPN (Synthetic preparation); PREP (Preparation)**
(photoreactions of amino-substituted endo tricyclodecadienones)
RN 220006-06-4 HCAPLUS
CN Acetamide, N-(octahydro-5-oxo-1,2,4-metheno-1H-cyclobuta[cd]pentalen-1-yl)-

N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 220006-07-5 HCAPLUS
CN Carbamic acid, (octahydro-5-oxo-1,2,4-metheno-1H-cyclobuta[cd]pentalen-1-yl)(phenylmethyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 220006-08-6 HCAPLUS
CN Benzeneacetamide, N-(octahydro-5-oxo-1,2,4-metheno-1H-cyclobuta[cd]pentalen-1-yl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 220006-09-7 HCAPLUS
CN Carbamic acid, (octahydro-5-oxo-1,2,4-metheno-1H-cyclobuta[cd]pentalen-1-yl)(phenylmethyl)-, phenylmethyl ester (9CI) (CA INDEX NAME)



L32 ANSWER 4 OF 15 HCAPLUS COPYRIGHT 2002 ACS
AN 1998:214962 HCAPLUS
DN 128:282758
TI Synthesis of certain N-{9-exo-[(dimethylamino- and pyrrolidino)methyl]tricyclo[5.2.1.02,6]decan-8-endo-yl}arylamides and -3,4-dichlorophenylacetamides with potential analgesic and local anesthetic activities
AU Aboul Enein, M. Nabil; El-Azzouny, Aida A.; Abdallah, Neveine A.; Maklad, Yousreya A.
CS Department Pharmaceutical Sciences, Pharmaceutical Chemistry Group, National Research Center, Cairo, Egypt
SO Sci. Pharm. (1998), 66(1), 59-76
CODEN: SCPHA4; ISSN: 0036-8709
PB Oesterreichische Apotheker-Verlagsgesellschaft
DT Journal
LA English
CC 27-10 (Heterocyclic Compounds (One Hetero Atom))
Section cross-reference(s): 1
AB The synthesis as well as the analgesic and local anesthetic activities of various 8-endo-acylamino-9-exo-[(dimethylamino- and pyrrolidino)methyl]tricyclo[5.2.1.02,6]decanes are described. The compd. with the highest analgesic activity (ED50 76.7 mg/kg, s.c) in the current series is much less active than morphine.HCl in hot-plate tests. All tested compds. exhibited noticeable local anesthetic potency compared with procaine.HCl (ED50 0.3 mg/kg, s.c) in twitch-response tests in guinea-pig skin.
ST aminomethyltricyclodecanyl amide analgesic local anesthetic prepn; tricyclodecanyl amide analgesic local anesthetic prepn
IT Analgesics
Local anesthetics
(prepn. and analgesic and local anesthetic activity of (acylamino)(aminomethyl)tricyclodecanes)
IT **205875-52-1P 205875-53-2P 205875-54-3P**
205875-55-4P 205875-56-5P 205875-57-6P
205875-58-7P 205875-59-8P 205875-61-2P
205875-63-4P 205875-64-5P 205875-65-6P
RL: BAC (Biological activity or effector, except adverse); **SPN (Synthetic preparation)**; BIOL (Biological study); **PREP (Preparation)**
(prepn. and analgesic and local anesthetic activity of (acylamino)(aminomethyl)tricyclodecanes)
IT 98-88-4, Benzoyl chloride 586-75-4, 4-Bromobenzoyl chloride 618-46-2, 3-Chlorobenzoyl chloride 6831-55-6, 3,4-Dichlorophenylacetyl chloride 7154-66-7, 2-Bromobenzoyl chloride 13380-94-4 25150-61-2, Pyrrolidine hydrochloride 29568-33-0, 5-Chloro-2-methoxybenzoyl chloride
RL: RCT (Reactant)
(prepn. and analgesic and local anesthetic activity of (acylamino)(aminomethyl)tricyclodecanes)
IT 205874-31-3P 205874-32-4P 205874-33-5P 205874-35-7P 205874-36-8P 205874-37-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and analgesic and local anesthetic activity of (acylamino)(aminomethyl)tricyclodecanes)
IT **205875-52-1P 205875-53-2P 205875-54-3P**
205875-55-4P 205875-56-5P 205875-57-6P
205875-58-7P 205875-59-8P 205875-61-2P
205875-63-4P 205875-64-5P 205875-65-6P
RL: BAC (Biological activity or effector, except adverse); **SPN**

(Synthetic preparation); BIOL (Biological study); **PREP (Preparation)**
(prepn. and analgesic and local anesthetic activity of (acylamino)(aminomethyl)tricyclodecanes)

RN 205875-52-1 HCAPLUS
CN Benzamide, N-[6-[(dimethylamino)methyl]octahydro-4,7-methano-1H-inden-5-yl]-, (4R,5S,6R,7S)-rel-[partial]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 205875-53-2 HCAPLUS
CN Benzamide, 3-chloro-N-[6-[(dimethylamino)methyl]octahydro-4,7-methano-1H-inden-5-yl]-, (4R,5S,6R,7S)-rel-[partial]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 205875-54-3 HCAPLUS
CN Benzamide, 2-bromo-N-[6-[(dimethylamino)methyl]octahydro-4,7-methano-1H-inden-5-yl]-, (4R,5S,6R,7S)-rel-[partial]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 205875-55-4 HCAPLUS
CN Benzamide, 4-bromo-N-[6-[(dimethylamino)methyl]octahydro-4,7-methano-1H-inden-5-yl]-, (4R,5S,6R,7S)-rel-[partial]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 205875-56-5 HCAPLUS
CN Benzamide, 5-chloro-N-[6-[(dimethylamino)methyl]octahydro-4,7-methano-1H-inden-5-yl]-2-methoxy-, (4R,5S,6R,7S)-rel-[partial]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 205875-57-6 HCAPLUS
CN Benzamide, 3,4-dichloro-N-[6-[(dimethylamino)methyl]octahydro-4,7-methano-1H-inden-5-yl]-, (4R,5S,6R,7S)-rel-[partial]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 205875-58-7 HCAPLUS
CN Benzamide, N-[octahydro-6-(1-pyrrolidinylmethyl)-4,7-methano-1H-inden-5-yl]-, (4R,5S,6R,7S)-rel-[partial]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 205875-59-8 HCAPLUS
CN Benzamide, 3-chloro-N-[octahydro-6-(1-pyrrolidinylmethyl)-4,7-methano-1H-inden-5-yl]-, (4R,5S,6R,7S)-rel-[partial]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 205875-61-2 HCAPLUS
CN Benzamide, 2-bromo-N-[octahydro-6-(1-pyrrolidinylmethyl)-4,7-methano-1H-inden-5-yl]-, (4R,5S,6R,7S)-rel-[partial]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 205875-63-4 HCAPLUS
CN Benzamide, 4-bromo-N-[octahydro-6-(1-pyrrolidinylmethyl)-4,7-methano-1H-inden-5-yl]-, (4R,5S,6R,7S)-rel-[partial]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 205875-64-5 HCAPLUS
CN Benzamide, 5-chloro-2-methoxy-N-[octahydro-6-(1-pyrrolidinylmethyl)-4,7-methano-1H-inden-5-yl]-, (4R,5S,6R,7S)-rel-[partial]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 205875-65-6 HCAPLUS
CN Benzamide, 3,4-dichloro-N-[octahydro-6-(1-pyrrolidinylmethyl)-4,7-methano-1H-inden-5-yl]-, (4R,5S,6R,7S)-rel-[partial]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L32 ANSWER 5 OF 15 HCAPLUS COPYRIGHT 2002 ACS
AN 1997:80139 HCAPLUS
DN 126:69744
TI Synthesis and Protein Kinase C Inhibitory Activities of Balanol Analogs with Replacement of the Perhydroazepine Moiety
AU Lai, Yen-Shi; Mendoza, Jose S.; Jagdmann, G. Erik, Jr.; Menaldino, David S.; Biggers, Christopher K.; Heerding, Julia M.; Wilson, Joseph W.; Hall, Steven E.; Jiang, Jack B.; et al.
CS Sphinx Pharmaceuticals, Durham, NC, 27707, USA
SO J. Med. Chem. (1997), 40(2), 226-235
CODEN: JMCMAR; ISSN: 0022-2623
PB American Chemical Society
DT Journal
LA English
CC 1-3 (Pharmacology)
Section cross-reference(s): 27
AB Balanol is a potent protein kinase C (PKC) inhibitor that is structurally composed of a benzophenone diacid, a 4-hydroxybenzamide, and a perhydroazepine ring. A no. of balanol analogs in which the perhydroazepine moiety is replaced have been synthesized and their biol. activities evaluated against both PKC and cAMP-dependent kinase (PKA). The results suggested that the activity and the isoenzyme/kinase selectivity of these compds. are largely related to the conformation about this nonarom. structural element of the mols.
ST balanol analog prepn kinase inhibition structure; protein kinase C inhibition balanol analog; cAMP dependent kinase inhibition balanol analog
IT Conformation
Structure-activity relationship
(synthesis and protein kinase C inhibitory activities of balanol analogs)
IT 285-67-6P, 6-Oxabicyclo[3.1.0]hexane 30708-54-4P, 1-Azabicyclo[3.2.2]nonan-4-one 31865-25-5P 31915-73-8P 59260-76-3P 66207-08-7P 88807-02-7P 167830-53-7P 167830-99-1P 167831-01-8P 167831-05-2P 167831-06-3P 167831-15-4P 167831-17-6P 167831-21-2P 167831-25-6P 167831-58-5P 167831-80-3P 167831-84-7P 167831-86-9P 167832-24-8P 167832-26-0P 167832-27-1P 167832-42-0P 167832-86-2P 169900-03-2P 170708-26-6P 170708-27-7P 170708-34-6P 170708-38-0P 170708-40-4P 170708-41-5P 170708-43-7P 170708-45-9P 170708-48-2P 170901-57-2P 170901-59-4P 170901-61-8P 170901-64-1P 171087-17-5P 171087-20-0P 171087-21-1P **171087-22-2P** 171235-43-1P 171598-49-5P 185423-55-6P 185423-56-7P 185423-63-6P 185423-65-8P

185423-66-9P 185423-67-0P **185423-68-1P**
RL: RCT (Reactant); **SPN (Synthetic preparation)**; **PREP (Preparation)**
(intermediate; synthesis and protein kinase C inhibitory activities of balanol analogs)

IT 109-96-6 142-29-0, Cyclopentene 532-24-1 628-92-2, Cycloheptene 1486-51-7 3731-38-2, 1-Azabicyclo[2.2.2]octan-3-one 6705-51-7, 7-Oxabicyclo[4.1.0]hept-2-ene 7686-77-3, 3-Cyclopentene-1-carboxylic acid 14320-37-7, 3-Cyclopenten-1-one 31970-04-4 34748-64-6 66207-23-6 158585-06-9 171028-69-6 171087-18-6 185423-62-5
RL: RCT (Reactant)
(reactant; synthesis and protein kinase C inhibitory activities of balanol analogs)

IT 167828-28-6P 167828-80-0P 167828-81-1P 167828-93-5P 167828-94-6P 167828-99-1P 167829-02-9P 167829-37-0P 167829-44-9P 167829-45-0P 167829-94-9P 167830-06-0P 167830-12-8P 170708-30-2P 170708-31-3P 170708-32-4P 170708-33-5P 170901-58-3P 170901-62-9P 170901-65-2P 171087-25-5P 171087-26-6P 171087-27-7P **171087-28-8P** 171087-29-9P
RL: BAC (Biological activity or effector, except adverse); **SPN (Synthetic preparation)**; THU (Therapeutic use); BIOL (Biological study); **PREP (Preparation)**; USES (Uses)
(synthesis and protein kinase C inhibitory activities of balanol analogs)

IT 63590-19-2, (-)-Balanol 167937-47-5 167937-49-7, (+)-Balanol
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(synthesis and protein kinase C inhibitory activities of balanol analogs)

IT 141436-78-4, Protein Kinase C 142008-29-5, CAMP-dependent protein kinase
RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
(synthesis and protein kinase C inhibitory activities of balanol analogs)

IT **171087-22-2P 185423-68-1P**
RL: RCT (Reactant); **SPN (Synthetic preparation)**; **PREP (Preparation)**
(intermediate; synthesis and protein kinase C inhibitory activities of balanol analogs)

RN 171087-22-2 HCAPLUS
CN Benzamide, N-(octahydro-6-hydroxy-4,7-methano-1H-inden-5-yl)-4-(phenylmethoxy)-, (3a.alpha.,4.beta.,5.alpha.,6.beta.,7.beta.,7a.beta.)-(9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 185423-68-1 HCAPLUS
CN Benzamide, N-(octahydro-6-hydroxy-4,7-methano-1H-inden-5-yl)-4-(phenylmethoxy)-, (3a.alpha.,4.beta.,5.beta.,6.beta.,7.beta.,7a.alpha.)-

(9CI) (CA INDEX NAME)

Relative stereochemistry.



IT **171087-28-8P**
RL: BAC (Biological activity or effector, except adverse); **SPN (Synthetic preparation)**; THU (Therapeutic use); BIOL (Biological study); **PREP (Preparation)**; USES (Uses)
(synthesis and protein kinase C inhibitory activities of balanol analogs)
RN 171087-28-8 HCAPLUS
CN Benzoic acid, 4-(2-carboxy-6-hydroxybenzoyl)-3,5-dihydroxy-, 1-[octahydro-6-[(4-hydroxybenzoyl)amino]-4,7-methano-1H-inden-5-yl] ester, (3a.alpha.,4.beta.,5.alpha.,6.beta.,7.beta.,7a.beta.)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L32 ANSWER 6 OF 15 HCAPLUS COPYRIGHT 2002 ACS
AN 1997:26988 HCAPLUS
DN 126:131247
TI Preparation and formulation of 1-benzamido-2-aroyloxy(bi)cycloalkanes and analogs as protein kinase C inhibitors
IN Hu, Hong; Jagdmann, G. Erik, Jr.; Mendoza, Jose S.
PA Eli Lilly and Company, USA
SO U.S., 24 pp. Cont.-in-part of U.S. Ser. No. 237,645, abandoned.
CODEN: USXXAM
DT Patent
LA English

IC ICM C07D487-00
ICS C07C069-76; A01N043-46; A01N037-10
NCL 540520000
CC 25-17 (Benzene, Its Derivatives, and Condensed Benzenoid Compounds)
Section cross-reference(s): 1, 63
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5583221	A	19961210	US 1995-392710	19950223
	CA 2189567	AA	19951116	CA 1995-2189567	19950315
	WO 9530640	A1	19951116	WO 1995-US3220	19950315
	W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TT, UA				
	RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9519989	A1	19951129	AU 1995-19989	19950315
	EP 758312	A1	19970219	EP 1995-913699	19950315
	EP 758312	B1	19991222		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	JP 10500106	T2	19980106	JP 1995-528935	19950315
	ES 2140672	T3	20000301	ES 1995-913699	19950315
PRAI	US 1994-237645	B2	19940504		
	US 1995-392710	A	19950223		
	WO 1995-US3220	W	19950315		

OS MARPAT 126:131247
GI



I

AB R5COZ1Z2Z3Z4NR1COR2 [R1 = H or alkyl; R2,R5 = disubstituted Ph with substituents selected from OH, CO2H, alkoxy, acyloxy, alkoxycarbonyl, etc.; Z1 = disubstituted 1,4-phenylene with substituents selected from OH, CO2H, alkoxy, acyloxy, alkoxycarbonyl, etc.; Z2 = CO or CH2; Z3 = O or (alkyl)imino; Z4 = fused or bridged divalent ring system optionally contg. heteroatoms] were prepd. as protein kinase C inhibitors (no data). Thus, anti-1-(4-benzyloxybenzamido)-2-indanol was esterified by 4-(6-benzyloxy-2-benzyloxycarbonylbenzoyl)-3,5-dibenzyloxybenzoic acid (prepn. each given) to give, after deprotection, title compd. anti-I.
ST benzamidoaroyloxycycloalkane prepn protein kinase C inhibitor
IT Antitumor agents
Cardiovascular agents
Nervous system agents
(prepn. and formulation of 1-benzamido-2-aroyloxy(bi)cycloalkanes and analogs as protein kinase C inhibitors)

IT 171087-25-5P 171087-27-7P 171235-51-1P 171235-53-3P 174600-44-3P
174600-45-4P 174600-46-5P 174600-47-6P 174600-48-7P 174600-52-3P
174600-54-5P 174600-55-6P 174600-56-7P 174691-45-3P 174756-90-2P
174756-91-3P 186099-83-2P 186099-84-3P 186099-85-4P 186099-86-5P
186099-87-6P 186099-88-7P 186099-89-8P 186099-90-1P 186099-91-2P
186379-93-1P 186379-94-2P
RL: BAC (Biological activity or effector, except adverse); **SPN (Synthetic preparation)**; THU (Therapeutic use); BIOL (Biological study); **PREP (Preparation)**; USES (Uses)
(prepn. and formulation of 1-benzamido-2-aroyloxy(bi)cycloalkanes and analogs as protein kinase C inhibitors)

IT 141436-78-4, Protein kinase C
RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
(prepn. and formulation of 1-benzamido-2-aroyloxy(bi)cycloalkanes and analogs as protein kinase C inhibitors)

IT 99-96-7, 4-Hydroxybenzoic acid, reactions 100-39-0, Benzyl bromide 497-38-1, Norcamphor 504-63-2, 1,3-Propanediol 532-24-1, 8-Methyl-8-azabicyclo[3.2.1]octan-3-one 1486-50-6, 4-Benzyloxybenzoyl chloride 1486-51-7, 4-Benzyloxybenzoic acid 2150-44-9, Methyl 3,5-dihydroxybenzoate 3146-39-2 3731-38-2, 3-Quinuclidinone 13286-59-4 13380-94-4, Tricyclo[5.2.1.02,6]decan-8-one 13575-72-9, 1H-Inden-1-ol, 2-amino-2,3-dihydro-, trans 18162-48-6, tert-Butyldimethylsilyl chloride 20445-33-4 22472-58-8 81245-35-4 158585-00-3, Benzenemethanol, 2-Bromo-3-phenylmethoxy- 158980-57-5
RL: RCT (Reactant)
(prepn. and formulation of 1-benzamido-2-aroyloxy(bi)cycloalkanes and analogs as protein kinase C inhibitors)

IT 25458-44-0P 28043-14-3P 30708-54-4P, 1-Azabicyclo[3.2.2]nonan-4-one 76280-59-6P, Methyl 3,5-bis(methoxymethoxy)benzoate 76280-60-9P
144337-52-0P 153923-07-0P 158584-99-7P 158585-06-9P 158980-61-1P
158980-62-2P 158980-63-3P 159425-38-4P 159425-41-9P 159425-42-0P
159425-43-1P 159425-44-2P 159425-45-3P 159425-46-4P 159425-47-5P
159425-49-7P 159425-50-0P 159425-51-1P 159425-52-2P 159425-53-3P
159425-55-5P 159425-56-6P 159425-57-7P 171087-18-6P 171087-19-7P
171087-20-0P 171087-23-3P 171087-24-4P 171235-48-6P 174600-57-8P
174600-58-9P 174600-59-0P 174600-60-3P 174600-61-4P 174600-64-7P
174600-65-8P 174600-66-9P 174600-74-9P 174600-75-0P 174600-78-3P
174600-79-4P 174600-80-7P 174600-81-8P 174600-83-0P 174600-84-1P
174600-85-2P 174600-86-3P 174691-49-7P 177472-72-9P 177472-73-0P
186099-92-3P 186099-93-4P 186099-94-5P 186099-95-6P 186099-96-7P
186099-97-8P 186099-98-9P 186099-99-0P 186100-00-5P
186100-01-6P 186100-02-7P 186100-03-8P
186100-04-9P
RL: RCT (Reactant); **SPN (Synthetic preparation)**; **PREP (Preparation)**
(prepn. and formulation of 1-benzamido-2-aroyloxy(bi)cycloalkanes and analogs as protein kinase C inhibitors)

IT **186379-93-1P 186379-94-2P**
RL: BAC (Biological activity or effector, except adverse); **SPN (Synthetic preparation)**; THU (Therapeutic use); BIOL (Biological study); **PREP (Preparation)**; USES (Uses)
(prepn. and formulation of 1-benzamido-2-aroyloxy(bi)cycloalkanes and analogs as protein kinase C inhibitors)

RN 186379-93-1 HCAPLUS
CN Benzoic acid, 4-(2-carboxy-6-hydroxybenzoyl)-3,5-dihydroxy-, 1-[octahydro-6-[(4-hydroxybenzoyl)amino]-4,7-methano-1H-inden-5-yl] ester, (4R,5R,6R,7S)-rel-[partial]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 186379-94-2 HCAPLUS
CN Benzoic acid, 4-(2-carboxy-6-hydroxybenzoyl)-3,5-dihydroxy-, 1-[octahydro-6-[(4-hydroxybenzoyl)amino]-4,7-methano-1H-inden-5-yl] ester, (4R,5S,6R,7S)-rel-[partial]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT **186100-01-6P 186100-02-7P 186100-03-8P 186100-04-9P**
RL: RCT (Reactant); **SPN (Synthetic preparation)**; **PREP (Preparation)**
(prepn. and formulation of 1-benzamido-2-aroyloxy(bi)cycloalkanes and analogs as protein kinase C inhibitors)
RN 186100-01-6 HCAPLUS
CN Benzamide, N-(octahydro-6-hydroxy-4,7-methano-1H-inden-5-yl)-4-(phenylmethoxy)-, (4R,5S,6S,7S)-rel-[partial]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 186100-02-7 HCAPLUS
CN Benzoic acid, 3,5-bis(phenylmethoxy)-4-[2-(phenylmethoxy)-6-[(phenylmethoxy)carbonyl]benzoyl]-, octahydro-6-[[4-(phenylmethoxy)benzoyl]amino]-4,7-methano-1H-inden-5-yl ester, (4R,5R,6R,7S)-rel-[partial]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 186100-03-8 HCAPLUS
CN Benzamide, N-(octahydro-6-hydroxy-4,7-methano-1H-inden-5-yl)-4-(phenylmethoxy)-, (4R,5S,6R,7S)-rel-[partial]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 186100-04-9 HCAPLUS
CN Benzoic acid, 3,5-bis(phenylmethoxy)-4-[2-(phenylmethoxy)-6-[(phenylmethoxy)carbonyl]benzoyl]-, octahydro-6-[[4-(phenylmethoxy)benzoyl]amino]-4,7-methano-1H-inden-5-yl ester, (4R,5S,6R,7S)-rel-[partial]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L32 ANSWER 7 OF 15 HCAPLUS COPYRIGHT 2002 ACS
AN 1996:171786 HCAPLUS
DN 124:232070
TI Preparation of substituted fused and bridged bicyclic compound protein kinase C inhibitors
IN Hu, Hong; Jagdmann, G. Erik, Jr.; Mendoza, Jose Serafin
PA Lilly, Eli, and Co., USA
SO PCT Int. Appl., 84 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM C07C069-76
ICS C07C233-00; C07C049-76; A01N037-12; A01N037-18
CC 25-23 (Benzene, Its Derivatives, and Condensed Benzenoid Compounds)
Section cross-reference(s): 1, 63
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9530640	A1	19951116	WO 1995-US3220	19950315
	W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TT, UA				
	RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US 5583221	A	19961210	US 1995-392710	19950223
	AU 9519989	A1	19951129	AU 1995-19989	19950315
	EP 758312	A1	19970219	EP 1995-913699	19950315
	EP 758312	B1	19991222		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE
JP 10500106 T2 19980106 JP 1995-528935 19950315
PRAI US 1994-237645 A 19940504
US 1995-392710 A 19950223
WO 1995-US3220 W 19950315
OS MARPAT 124:232070
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. [I; A = (un)substituted NH, O; R1 = H, alkyl; R2-R6 = HO, alkoxy, alkoxycarbonyl, CO2H, CHO, halogen, alkyl, etc.; R7 = H, R2-R6; X = CO, CH2; ring = fused or bridged bicyclic ring optionally contg. heteroatoms], useful as inhibitors of protein kinase C and as anticancer and antiinflammatory agents, are prepd. and I-contg. formulations presented. Thus, indane deriv. II, m.p. 160-162.degree., prepd. in a multi-step process from 4-[6-benzyloxy-2-(benzyloxycarbonyl)benzoyl]-3,5-di(benzyloxy)benzoic acid, demonstrated a IC50 of 50 .mu.M against the K562 chronic myeloid leukemia cell line.

ST indane prepn protein kinase inhibitor; anticancer agent prepn indane; antiinflammatory agent prepn indane

IT Inflammation inhibitors
Neoplasm inhibitors
(substituted fused and bridged bicyclic compd. protein kinase C inhibitors)

IT 141436-78-4, Protein kinase C
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(prepn. of substituted fused and bridged bicyclic compd. inhibitors of)

IT 171087-25-5P 171087-27-7P 171235-51-1P 171235-53-3P 174600-44-3P
174600-45-4P 174600-46-5P 174600-47-6P 174600-48-7P 174600-49-8P
174600-50-1P 174600-51-2P 174600-52-3P 174600-53-4P 174600-54-5P
174600-55-6P 174600-56-7P 174691-43-1P 174691-44-2P 174691-45-3P
174691-46-4P **174691-47-5P** 174756-90-2P 174756-91-3P
RL: BAC (Biological activity or effector, except adverse); **SPN (Synthetic preparation)**; THU (Therapeutic use); BIOL (Biological study); **PREP (Preparation)**; USES (Uses)
(prepn. of substituted fused and bridged bicyclic compd. protein kinase C inhibitors)

IT 100-39-0, Benzyl bromide 107-30-2, Methoxymethyl chloride 497-38-1, Norcamphor 504-63-2, 1,3-Propanediol 532-24-1, 8-Methyl-8-azabicyclo[3.2.1]octan-3-one 1486-50-6, 4-Benzyloxybenzoyl chloride 1486-51-7, 4-Benzyloxybenzoic acid 2150-44-9, Methyl 3,5-dihydroxybenzoate 3146-39-2, exo-2,3-Epoxynorbornane 3731-38-2, Quinuclidin-3-one 13286-59-4 13380-94-4 18162-48-6, tert-Butyldimethylsilyl chloride 20445-33-4 22472-58-8 81245-35-4 158585-00-3 158980-57-5 159425-38-4 170708-15-3
RL: RCT (Reactant)
(prepn. of substituted fused and bridged bicyclic compd. protein kinase C inhibitors)

IT 1925-45-7P 23337-80-6P 27888-28-4P 28043-14-3P 30708-54-4P, 1-Azabicyclo[3.2.2]nonan-4-one 129705-76-6P 144337-52-0P
158584-99-7P 158585-06-9P 158980-61-1P 158980-62-2P 158980-63-3P
159425-41-9P 159425-42-0P 159425-43-1P 159425-44-2P 159425-45-3P
159425-46-4P 159425-47-5P 159425-49-7P 159425-50-0P 159425-51-1P
159425-52-2P 159425-53-3P 159425-55-5P 159425-56-6P 159425-57-7P
167832-93-1P 171087-17-5P 171087-18-6P 171087-19-7P 171087-20-0P

171087-23-3P 171087-24-4P 171235-48-6P 171598-49-5P 174600-57-8P
174600-58-9P 174600-59-0P 174600-60-3P 174600-61-4P 174600-62-5P
174600-63-6P 174600-64-7P 174600-65-8P 174600-66-9P 174600-67-0P
174600-68-1P 174600-69-2P 174600-70-5P 174600-71-6P 174600-72-7P
174600-73-8P 174600-74-9P 174600-75-0P **174600-76-1P**
174600-77-2P 174600-78-3P 174600-79-4P 174600-80-7P 174600-81-8P
174600-82-9P 174600-83-0P 174600-84-1P 174600-85-2P 174600-86-3P
174600-87-4P 174691-48-6P 174691-49-7P **174691-50-0P**
174691-51-1P 174691-52-2P
RL: RCT (Reactant); **SPN (Synthetic preparation)**; **PREP (Preparation)**
(prepn. of substituted fused and bridged bicyclic compd. protein kinase C inhibitors)

IT 174600-88-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of substituted fused and bridged bicyclic compd. protein kinase C inhibitors)

IT **174691-47-5P**
RL: BAC (Biological activity or effector, except adverse); **SPN (Synthetic preparation)**; THU (Therapeutic use); BIOL (Biological study); **PREP (Preparation)**; USES (Uses)
(prepn. of substituted fused and bridged bicyclic compd. protein kinase C inhibitors)

RN 174691-47-5 HCAPLUS
CN Benzoic acid, 4-(2-carboxy-6-hydroxybenzoyl)-3,5-dihydroxy-, 1-[octahydro-6-[(4-hydroxybenzoyl)amino]-4,7-methano-1H-inden-5-yl] ester (9CI) (CA INDEX NAME)



IT **174600-76-1P 174691-50-0P 174691-51-1P**
RL: RCT (Reactant); **SPN (Synthetic preparation)**; **PREP (Preparation)**
(prepn. of substituted fused and bridged bicyclic compd. protein kinase C inhibitors)

RN 174600-76-1 HCAPLUS
CN Benzoic acid, 3,5-bis(phenylmethoxy)-4-[2-(phenylmethoxy)-6-[(phenylmethoxy)carbonyl]benzoyl]-, octahydro-6-[[4-(phenylmethoxy)benzoyl]amino]-4,7-methano-1H-inden-5-yl ester (9CI) (CA INDEX NAME)



RN 174691-50-0 HCAPLUS
CN Benzamide, N-(octahydro-6-hydroxy-4,7-methano-1H-inden-5-yl)-4-(phenylmethoxy)- (9CI) (CA INDEX NAME)



RN 174691-51-1 HCAPLUS
CN Benzoic acid, 4-(2-carboxy-6-hydroxybenzoyl)-3,5-dihydroxy-, 1-[octahydro-6-[(4-hydroxybenzoyl)amino]-4,7-methano-1H-inden-5-yl] ester, trifluoroacetate (4:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 174691-47-5
CMF C32 H29 N O10



CM 2

CRN 76-05-1
CMF C2 H F3 O2



L32 ANSWER 8 OF 15 HCAPLUS COPYRIGHT 2002 ACS
AN 1995:857588 HCAPLUS
DN 124:29467
TI Synthesis and biological evaluation of conformationally constrained bicyclic and tricyclic balanol analogs as inhibitors of protein kinase C
AU Mendoza, Jose S.; Jagdmann, G. Erik, Jr.; Gosnell, Paul A.
CS a Division of Eli Lilly & Company, Sphinx Pharmaceuticals, Durham, NC, 27707, USA
SO Bioorg. Med. Chem. Lett. (1995), 5(19), 2211-16
CODEN: BMCLE8; ISSN: 0960-894X
DT Journal
LA English
CC 26-6 (Biomolecules and Their Synthetic Analogs)
Section cross-reference(s): 1, 7
GI



AB A series of conformationally constrained bicyclic and tricyclic balanol analogs was prepd. and evaluated as inhibitors of protein kinase C (PKC). Of special interest are bicyclic balanol analogs I and II and the tricyclic analog III [R2 = COC6H4OH-4], which not only retain the nanomolar activity for most PKC isoenzymes, but also display good selectivity over c-AMP dependent protein kinase (PKA).
ST balanol bicyclic tricyclic analog; protein kinase inhibitor balanol analog
IT 63590-19-2DP, (-)-Balanol, bi- and tricyclic analogs 171087-25-5P 171087-26-6P 171087-27-7P **171087-28-8P** 171087-29-9P 171235-51-1P 171235-52-2P 171235-53-3P **171235-54-4P**
RL: BAC (Biological activity or effector, except adverse); **SPN (Synthetic preparation)**; BIOL (Biological study); **PREP (Preparation)**
(prepn. of conformationally constrained bicyclic and tricyclic balanol

analogs as inhibitors of protein kinase C)

IT 141436-78-4, Protein kinase C
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(prepn. of conformationally constrained bicyclic and tricyclic balanol analogs as inhibitors of protein kinase C)

IT 3731-38-2, 1-Azabicyclo[2.2.2]octan-3-one 28043-14-3 167832-93-1 171087-20-0 171087-22-2 171087-23-3 171235-50-0
RL: RCT (Reactant)
(prepn. of conformationally constrained bicyclic and tricyclic balanol analogs as inhibitors of protein kinase C)

IT 30708-54-4P, 1-Azabicyclo[3.2.2]nonan-4-one 171087-17-5P 171087-18-6P 171087-19-7P 171087-21-1P 171087-24-4P 171235-48-6P 171235-49-7P 171598-49-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. of conformationally constrained bicyclic and tricyclic balanol analogs as inhibitors of protein kinase C)

IT **171087-28-8P 171235-54-4P**
RL: BAC (Biological activity or effector, except adverse); **SPN (Synthetic preparation)**; BIOL (Biological study); **PREP (Preparation)**
(prepn. of conformationally constrained bicyclic and tricyclic balanol analogs as inhibitors of protein kinase C)

RN 171087-28-8 HCAPLUS
CN Benzoic acid, 4-(2-carboxy-6-hydroxybenzoyl)-3,5-dihydroxy-, 1-[octahydro-6-[(4-hydroxybenzoyl)amino]-4,7-methano-1H-inden-5-yl] ester, (3a.alpha.,4.beta.,5.alpha.,6.beta.,7.beta.,7a.beta.)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 171235-54-4 HCAPLUS
CN Benzoic acid, 4-(2-carboxy-6-hydroxybenzoyl)-3,5-dihydroxy-, 1-[octahydro-6-[(4-hydroxybenzoyl)amino]-4,7-methano-1H-inden-5-yl] ester, (3a.alpha.,4.beta.,5.alpha.,6.alpha.,7.beta.,7a.alpha.)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L32 ANSWER 9 OF 15 HCAPLUS COPYRIGHT 2002 ACS
AN 1994:408589 HCAPLUS
DN 121:8589
TI Isomerization reactions of dicyclopentadiene derivatives. Preparation of amides and carboxylic acids
AU Bakke, Jan M.; Knudsen, Boore
CS Norwegian Inst. Technol., Univ. Trondheim, Trondheim, N-7034, Norway
SO Acta Chem. Scand. (1994), 48(3), 234-9
CODEN: ACHSE7; ISSN: 0904-213X
DT Journal
LA English
CC 22-13 (Physical Organic Chemistry)
OS CASREACT 121:8589
GI



I II III

AB The dicyclopentadiene (DPD) derivs. 8,9-endo-dihydro-DPD (I), 8-exo-hydroxy-exo-tetrahydro-DPD (II), and 2-hydroxy-endo-tetrahydro-DPD (III) have been reacted with acetonitrile in sulfuric acid. Reaction for 6 h at 30.degree.C gave an 82% yield of N-(2-exo-tetrahydro-DPD-yl)acetamide. Reaction of III for 1 min at 20.degree.C gave N-(2-endo-tetrahydro-DPD-yl)acetamide (95% yield) and reaction of II with acetonitrile and boron trifluoride in sulfur dioxide gave a 95% yield of N-(exo-8-exo-tetrahydro-DPD-yl)acetamide. The reactions of III with benzonitrile and substituted benzonitriles were monitored by 1H NMR spectroscopy. The obsd. rate consts. could be correlated by the Hammett .sigma.- consts. with a .rho. const. of 1.00 (R2 = 0.987). These results were in accordance with a reaction scheme in which the isomerizations proceed via carbocations in equil. with nitrile adducts. Reaction of 8-exo-chloro-exo-tetrahydro-DPD with carbon monoxide and antimony pentafluoride in sulfur dioxide gave 2-carboxy-endo-tetrahydro-DPD at

-78.degree.C and 2-carboxy-exo-2-tetrahydro-DPD at 20.degree.C.

ST Ritter reaction dicyclopentadiene deriv nitrile; amide dicyclopentadiene deriv; carboxylic acid dicyclopentadiene deriv

IT Kinetics of addition reaction
(Ritter, of dicyclopentadiene derivs. with nitriles in presence of acid)

IT Linear free energy relationship
Reaction constant
(for reaction of dicyclopentadiene derivs. with nitriles in presence of acid)

IT Isomerization
(in reactions of dicyclopentadiene derivs. with nitriles in presence of acid)

IT Nitriles, reactions
RL: RCT (Reactant)
(reaction of, with dicyclopentadiene derivs. in presence of acid)

IT Addition reaction
(Ritter, of dicyclopentadiene derivs. with nitriles in presence of acid)

IT 80394-98-5P 80433-66-5P 155507-23-6P 155507-24-7P 155507-25-8P
155507-26-9P 155507-27-0P **155507-28-1P** 155507-29-2P
155507-30-5P 155551-00-1P
RL: **SPN (Synthetic preparation)**; **PREP (Preparation)**
(prepn. of)

IT 56914-94-4
RL: RCT (Reactant)
(reaction of, with carbon dioxide in superacid)

IT 75-05-8, Acetonitrile, reactions 100-47-0, Benzonitrile, reactions 104-85-8, p-Methylbenzonitrile 619-72-7, p-Nitrobenzonitrile 623-03-0, p-Chlorobenzonitrile
RL: RCT (Reactant)
(reaction of, with dicyclopentadiene derivs. in presence of acid)

IT 77-73-6, Dicyclopentadiene 2825-86-7 10271-44-0 86594-77-6
RL: RCT (Reactant)
(reactions of, with nitriles in presence of acid, isomerization in)

IT **155507-26-9P 155507-28-1P 155507-30-5P**
RL: **SPN (Synthetic preparation)**; **PREP (Preparation)**
(prepn. of)

RN 155507-26-9 HCAPLUS

CN Benzamide, N-(octahydro-4,7-methano-1H-inden-5-yl)-, (3a.alpha.,4.beta.,5.beta.,7.beta.,7a.alpha.)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 155507-28-1 HCAPLUS

CN Benzamide, 4-chloro-N-(octahydro-4,7-methano-1H-inden-5-yl)-, (3a.alpha.,4.beta.,5.beta.,7.beta.,7a.alpha.)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 155507-30-5 HCAPLUS
CN Benzamide, 4-nitro-N-(octahydro-4,7-methano-1H-inden-5-yl)-, (3a.alpha.,4.beta.,5.beta.,7.beta.,7a.alpha.)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L32 ANSWER 10 OF 15 HCAPLUS COPYRIGHT 2002 ACS
AN 1991:35854 HCAPLUS
DN 114:35854
TI Synthesis of certain spirohexahydro-4,7-methanoindanpiperazine derivatives as analgesics
AU Aboul-Enein, M. N.; Maklouf, A. M. A.; El-Azzouny, A. A.
CS Lab. Pharm. Sci., Natl. Res. Cent., Dokki, Egypt
SO Sci. Pharm. (1990), 58(3), 263-71
CODEN: SCPHA4; ISSN: 0036-8709
DT Journal
LA English
CC 1-11 (Pharmacology)
Section cross-reference(s): 28
GI



I



II, X=NH
III, X=O

AB Title compds. (I and II, R = Ph, 4-MeC6H4, 4-MeOC6H4, PhCH2), were prepd. from the corresponding aminohexahydro-4,7-methanoindan-5-carbonitriles by

modified Strecker synthesis, acid hydrolysis, cyanomethylation and reaction with ethylenediamine hydrolysis and tested for their analgesic activity in a mouse hot-plate test. Compd. I (R = 4-MeOC6H4) exhibited the highest activity with an ED50 of 9.9 mg/kg compared to morphine-HCl with an ED50 of 7.3 mg/kg. Structure-activity relations for I and II are discussed.

ST spirohexahydromethanoindanpiperazine deriv prepn analgesic

IT Analgesics
(spirohexahydromethanoindanpiperazine derivs., prepn. of, structure in relation to)

IT Molecular structure-biological activity relationship
(analgesic, of spirohexahydromethanoindanpiperazine derivs.)

IT 13380-94-4
RL: RCT (Reactant)
(Strecker reaction of)

IT 131466-07-4P 131466-08-5P 131466-09-6P 131466-10-9P 131466-11-0P
131466-12-1P 131466-13-2P 131466-14-3P 131466-15-4P 131466-16-5P
131466-17-6P 131466-18-7P
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. and analgesic activity of, structure in relation to)

IT 131466-23-4P 131466-24-5P 131466-25-6P **131466-26-7P**
RL: RCT (Reactant); **SPN (Synthetic preparation); PREP (Preparation)**
(prepn. and cyanomethylation of)

IT 131466-27-8P 131466-28-9P 131466-29-0P **131466-30-3P**
RL: RCT (Reactant); **SPN (Synthetic preparation); PREP (Preparation)**
(prepn. and cyclization of)

IT 131466-19-8P 131466-20-1P **131466-22-3P**
RL: RCT (Reactant); **SPN (Synthetic preparation); PREP (Preparation)**
(prepn. and hydrolysis of, carboxamide formation in)

IT 131466-21-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

IT **131466-26-7P**
RL: RCT (Reactant); **SPN (Synthetic preparation); PREP (Preparation)**
(prepn. and cyanomethylation of)

RN 131466-26-7 HCAPLUS

CN 4,7-Methano-1H-indene-5-carboxamide, octahydro-5-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)



IT **131466-30-3P**
RL: RCT (Reactant); **SPN (Synthetic preparation); PREP (Preparation)**
(prepn. and cyclization of)

RN 131466-30-3 HCAPLUS

CN 4,7-Methano-1H-indene-5-carboxamide, 5-[(cyanomethyl)(phenylmethyl)amino]octahydro- (9CI) (CA INDEX NAME)



IT **131466-22-3P**
RL: RCT (Reactant); **SPN (Synthetic preparation)**; **PREP (Preparation)**
(prepn. and hydrolysis of, carboxamide formation in)
RN 131466-22-3 HCAPLUS
CN 4,7-Methano-1H-indene-5-carbonitrile, octahydro-5-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)



L32 ANSWER 11 OF 15 HCAPLUS COPYRIGHT 2002 ACS
AN 1987:438842 HCAPLUS
DN 107:38842
TI Electrochemical 1-adamantylation and tetrahydro-exo-dicyclopentadien-9-ylation of azomethines
AU Hess, U.; Lieberenz, C.; Feuerherd, B.
CS Sekt. Chem., Humboldt-Univ. Berlin, Berlin, DDR-1040, Ger. Dem. Rep.
SO J. Prakt. Chem. (1986), 328(1), 7-20
CODEN: JPCEAO; ISSN: 0021-8383
DT Journal
LA German
CC 22-4 (Physical Organic Chemistry)
Section cross-reference(s): 72
OS CASREACT 107:38842
GI

AB Azomethine adducts I (R = Ph, p-tolyl, 2-pyridyl, 2-quinolyl; R1 = H, Me; R2 = Me, Ph, arylalkyl) and II (R = Ph, p-anisyl) were prepd. by

electrochem. reactions of azomethines with 1-bromoadamantane and 9-bromotetrahydro-exo-dicyclopentadiene. In the SET mechanism bridgehead radicals couple with azomethine anion radicals at the position of highest unpaired electron d., normally the C of the C:N group.

ST azomethine electrochem addn adamantane tetrahydrodicyclopentadiene; dicyclopentadiene tetrahydro electrochem addn azomethine

IT Schiff bases
RL: RCT (Reactant)
(electrochem. alkylation of, mechanism of)

IT Electron configuration
(of benzylideneaniline, electrochem. alkylation in relation to)

IT Alkylation
(electrochem., of azomethines by bromoadamantane and bromotetrahydrodicyclopentadiene)

IT 768-90-1, 1-Bromoadamantane 81012-71-7
RL: RCT (Reactant)
(electrochem. reaction of, with azomethines)

IT 538-51-2 622-29-7 780-25-6 836-41-9 1749-19-5 2980-02-1 3129-98-4 5603-13-4 7032-25-9 10133-74-1 30403-97-5 66040-49-1
RL: RCT (Reactant)
(electrochem. reaction of, with satd. polycyclic bromides)

IT 103-32-2P 103-49-1P 779-54-4P 3526-43-0P 4329-81-1P 29334-75-6P 89516-06-3P **89516-07-4P** 107909-51-3P 107909-52-4P 107909-53-5P 107909-54-6P 107909-55-7P 107909-56-8P 107909-57-9P 107909-58-0P 107909-59-1P 107909-60-4P 107909-61-5P 107909-62-6P 107909-63-7P 107909-64-8P 107909-65-9P 107909-66-0P 107909-67-1P 107938-59-0P
RL: **SPN (Synthetic preparation); PREP (Preparation)**
(prepn. of)

IT **89516-07-4P**
RL: **SPN (Synthetic preparation); PREP (Preparation)**
(prepn. of)

RN 89516-07-4 HCAPLUS

CN 4,7-Methano-1H-inden-5-amine, octahydro-N,N-bis(phenylmethyl)- (9CI) (CA INDEX NAME)



L32 ANSWER 12 OF 15 HCAPLUS COPYRIGHT 2002 ACS

AN 1985:197548 HCAPLUS

DN 102:197548

TI Synthesis and pharmacological activity of derivatives of exo-trimethylenenorbornane. V

AU Longobardi, M.; Schenone, P.; Bargagna, A.; Matera, C.; Rossi, F.; Marmo, E.

CS Ist. Sci. Farm., Univ. Genova, Genoa, Italy

SO Farmaco, Ed. Sci. (1985), 40(3), 162-9
CODEN: FRPSAX; ISSN: 0430-0920

DT Journal

LA English

CC 1-4 (Pharmacology)
Section cross-reference(s): 25

GI



I



II

AB Seven amides I (R = CH2Cl, Me, cyclopropyl, CH:CHPh, Ph, 4-NO2C6H4, and 4-H2NC6H4) and 6 glycinamides II (R = NEt2, NMe(CH2)2NMe2, pyrrolidino, piperidino, morpholino, N'-methylpiperazino) derived from N-phenyl-exo-5,6-trimethylenenorbornan-2-endo-amine [96356-45-5] were prepd. and tested for pharmacol. activity. All of the I derivs. showed moderate hypotensive activity whereas some of the I and II derivs. had weak local anesthetic and antiarrhythmic activity. The effects of the compds. on heart rate are also described.

ST trimethylenorbornane amide glycinamide prepn pharmacol

IT Antiarrhythmics
Antihypertensives
(phenyltrimethylenenorbornanyl amides and glycinamides)

IT Anesthetics
(local, phenyltrimethylenenorbornanyl amides and glycinamides)

IT 96356-32-0P **96356-33-1P 96356-34-2P**
96356-36-4P 96356-38-6P 96356-39-7P 96356-40-0P
96356-41-1P 96356-42-2P 96356-43-3P 96380-84-6P
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); **SPN (Synthetic preparation)**; THU (Therapeutic use); BIOL (Biological study); **PREP (Preparation)**; PROC (Process); USES (Uses)
(prepn. and pharmacol. of)

IT 96356-45-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and reaction with acyl chlorides)

IT 96356-37-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and reaction with secondary amines)

IT **96356-35-3P** 96356-44-4P
RL: RCT (Reactant); **SPN (Synthetic preparation)**; **PREP (Preparation)**
(prepn. and redn. of)

IT 34748-64-6
RL: RCT (Reactant)
(reaction of, with aniline)

IT 109-01-3 109-89-7, reactions 110-89-4, reactions 110-91-8, reactions 123-75-1, reactions 142-25-6
RL: RCT (Reactant)
(reaction of, with chlorophenyltrimethylenenorbornanylacetamide)

IT 75-36-5 79-04-9 98-88-4 4023-34-1 17082-09-6
RL: RCT (Reactant)
(reaction of, with phenyltrimethylenenorbornanamine)

IT 62-53-3, reactions
RL: RCT (Reactant)
(reaction of, with trimethylenenorbornanone)

IT **96356-33-1P 96356-34-2P 96356-36-4P**
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); **SPN (Synthetic preparation)**; THU (Therapeutic use);

BIOL (Biological study); **PREP (Preparation)**; PROC (Process);
USES (Uses)
(prepn. and pharmacol. of)

RN 96356-33-1 HCAPLUS
CN 2-Propenamide, N-(octahydro-4,7-methano-1H-inden-5-yl)-N,3-diphenyl-, (3a.alpha.,4.beta.,5.alpha.,7.beta.,7a.alpha.)- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 96356-34-2 HCAPLUS
CN Benzamide, N-(octahydro-4,7-methano-1H-inden-5-yl)-N-phenyl-, (3a.alpha.,4.beta.,5.alpha.,7.beta.,7a.alpha.)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 96356-36-4 HCAPLUS
CN Benzamide, 4-amino-N-(octahydro-4,7-methano-1H-inden-5-yl)-N-phenyl-, (3a.alpha.,4.beta.,5.alpha.,7.beta.,7a.alpha.)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT **96356-35-3P**
RL: RCT (Reactant); **SPN (Synthetic preparation)**; **PREP (Preparation)**
(prepn. and redn. of)

RN 96356-35-3 HCAPLUS
CN Benzamide, 4-nitro-N-(octahydro-4,7-methano-1H-inden-5-yl)-N-phenyl-, (3a.alpha.,4.beta.,5.alpha.,7.beta.,7a.alpha.)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L32 ANSWER 13 OF 15 HCAPLUS COPYRIGHT 2002 ACS
AN 1984:156514 HCAPLUS
DN 100:156514
TI 9(10)-Substituted 9,10-dihydro- and tetrahydro-exo-dicyclopentadienes
IN Hess, Ulrich; Feuerherd, Bernd
PA Humboldt-Universitaet zu Berlin, Ger. Dem. Rep.
SO Ger. (East), 11 pp.
CODEN: GEXXA8
DT Patent
LA German
IC C07C013-61; C07C087-453; C25B003-10
CC 27-17 (Heterocyclic Compounds (One Hetero Atom))
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DD 202863	A1	19831005	DD 1981-235451	19811205

PI
GI



I

AB The dicyclopentadienes I (R = N heterocyclic, aminomethyl, tertiary amino) and their 1,2- and 2,3-didehydro derivs. were prepd. Thus, I (R = Br) was electrolyzed with quinoline to give 36% I (R = 2-quinolyl).
ST aminodicyclopentadiene; tricyclodecanamine; quinolyltricyclodecane
IT 55101-72-9 81012-71-7
RL: RCT (Reactant)
(electrolysis of, with amines)
IT 91-22-5, reactions 103-31-1 538-51-2 588-59-0 615-20-3 780-25-6
RL: RCT (Reactant)
(electrolysis of, with bromotetrahydrodicyclopentadiene)
IT 89509-09-1P 89509-10-4P 89509-11-5P 89509-12-6P 89516-04-1P 89516-05-2P 89516-06-3P **89516-07-4P**
RL: **SPN (Synthetic preparation); PREP (Preparation)**
(prepn. of)
IT **89516-07-4P**

RL: **SPN (Synthetic preparation); PREP (Preparation)**
(prepn. of)
RN 89516-07-4 HCAPLUS
CN 4,7-Methano-1H-inden-5-amine, octahydro-N,N-bis(phenylmethyl)- (9CI) (CA INDEX NAME)



L32 ANSWER 14 OF 15 HCAPLUS COPYRIGHT 2002 ACS
AN 1980:163608 HCAPLUS
DN 92:163608
TI Synthesis and pharmacological activity of derivatives of exo-trimethylenenorbornane. I
AU Bondavalli, F.; Lanteri, S.; Longobardi, M.; Schenone, P.
CS Ist. Sci. Farm., Univ. Genova, Genoa, Italy
SO Farmaco, Ed. Sci. (1979), 34(11), 945-51
CODEN: FRPSAX; ISSN: 0430-0920
DT Journal
LA English
CC 24-7 (Alicyclic Compounds)
GI

I

AB LiAlH4 redn. of oxime I (RR1 = NOH) gave endo-amine I (R = H, R1 = NH2), which was acylated with ClCOR2 (R2 = Me, Ph, C6H4NO2-p, C6H2(OMe)3, CHPh2, cyclopropyl) to give I (R = H, R1 = NHCOR2), whose redn. gave amines I (R = H, R1 = NHCH2R2). I (R = H; R1 = NHAc, NHCOC6H4NH2-4, cyclopropylcarboxamido) had weak depressant activity and I (R = H, R1 = cycloprpylmethylamino) was a convulsant.
ST trimethylnorbornane deriv pharmacolog activity; norbornane trimethylene pharmacolog activity
IT Central nervous system depressants
(trimethylenenorbornane derivs.)
IT 75-36-5 98-88-4 122-04-3 1871-76-7 4023-34-1 4521-61-3 16106-38-0
RL: RCT (Reactant)
(acylation by, of aminotrimethylenenorbornane)
IT 50-55-5
RL: RCT (Reactant)
(antagonists for, trimethylenenorbornane deriv. as)
IT 73365-80-7
RL: RCT (Reactant)
(hydride redn. of)

IT 73335-94-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and acylation of)
IT 73336-02-4P **73336-03-5P 73336-04-6P**
73336-05-7P 73336-06-8P 73336-07-9P
RL: BAC (Biological activity or effector, except adverse); **SPN (Synthetic preparation)**; THU (Therapeutic use); BIOL (Biological study); **PREP (Preparation)**; USES (Uses)
(prepn. and pharmacol. activities of)
IT 73341-68-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
IT 73335-95-2P **73335-96-3P 73335-97-4P**
73335-98-5P 73335-99-6P 73336-00-2P
73336-01-3P
RL: RCT (Reactant); **SPN (Synthetic preparation)**; **PREP (Preparation)**
(prepn., redn., and pharmacol. activities of)
IT **73336-03-5P 73336-04-6P 73336-05-7P**
73336-06-8P
RL: BAC (Biological activity or effector, except adverse); **SPN (Synthetic preparation)**; THU (Therapeutic use); BIOL (Biological study); **PREP (Preparation)**; USES (Uses)
(prepn. and pharmacol. activities of)
RN 73336-03-5 HCAPLUS
CN 4,7-Methano-1H-inden-5-amine, octahydro-N-(phenylmethyl)-, (3a.alpha.,4.beta.,5.alpha.,7.beta.,7a.alpha.)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 73336-04-6 HCAPLUS
CN 4,7-Methano-1H-inden-5-amine, N-[(4-aminophenyl)methyl]octahydro-, dihydrochloride, (3a.alpha.,4.beta.,5.alpha.,7.beta.,7a.alpha.)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



●2 HCl

RN 73336-05-7 HCAPLUS
CN 4,7-Methano-1H-inden-5-amine, octahydro-N-[(3,4,5-trimethoxyphenyl)methyl]-, hydrochloride, (3a.alpha.,4.beta.,5.alpha.,7.beta.,7a.alpha.)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 73336-06-8 HCAPLUS
CN 4,7-Methano-1H-inden-5-amine, N-(2,2-diphenylethyl)octahydro-, hydrochloride, (3a.alpha.,4.beta.,5.alpha.,7.beta.,7a.alpha.)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

IT **73335-96-3P 73335-97-4P 73335-98-5P**
73335-99-6P 73336-00-2P
RL: RCT (Reactant); **SPN (Synthetic preparation)**; **PREP (Preparation)**
(prepn., redn., and pharmacol. activities of)
RN 73335-96-3 HCAPLUS
CN Benzamide, N-(octahydro-4,7-methano-1H-inden-5-yl)-, (3a.alpha.,4.beta.,5.alpha.,7.beta.,7a.alpha.)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 73335-97-4 HCAPLUS
CN Benzamide, 4-nitro-N-(octahydro-4,7-methano-1H-inden-5-yl)-, (3a.alpha.,4.beta.,5.alpha.,7.beta.,7a.alpha.)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 73335-98-5 HCAPLUS
CN Benzamide, 4-amino-N-(octahydro-4,7-methano-1H-inden-5-yl)-, (3a.alpha.,4.beta.,5.alpha.,7.beta.,7a.alpha.)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 73335-99-6 HCAPLUS
CN Benzamide, 3,4,5-trimethoxy-N-(octahydro-4,7-methano-1H-inden-5-yl)-, (3a.alpha.,4.beta.,5.alpha.,7.beta.,7a.alpha.)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 73336-00-2 HCAPLUS
CN Benzeneacetamide, N-(octahydro-4,7-methano-1H-inden-5-yl)-.alpha.-phenyl-, (3a.alpha.,4.beta.,5.alpha.,7.beta.,7a.alpha.)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L32 ANSWER 15 OF 15 HCAPLUS COPYRIGHT 2002 ACS
AN 1970:110661 HCAPLUS
DN 72:110661
TI Stereospecific addition of carbon and nitrogen nucleophiles to dicyclopentadieneplatinum and -palladium complexes
AU Stille, John K.; Fox, Dale B.
CS Dep. of Chem., Univ. of Iowa, Iowa City, Iowa, USA
SO J. Amer. Chem. Soc. (1970), 92(5), 1274-8

CODEN: JACSAT
DT Journal
LA English
CC 22 (Physical Organic Chemistry)
AB The nucleophilic addns. of acetylacetone, Et acetoacetate, diethyl malonate, or PhCH2NH2 to the double bond of dichloro(endo-dicyclopentadiene)platinum(II) and of thallous acetylacetone to dichloro(endo-dicyclopentadiene)palla-dium(II) produced platinum- and palladium-carbon .sigma.-bonded complexes. The trans addns. take place at the 5,6-double bond without skeletal rearrangement of the dicyclopentadiene moiety; the nucleophile is attached exo with the metal endo and coordi-nated to the 2,3-double bond.
ST metals; stereospecific addn nucleophiles dicyclopentadiene; addn stereospecific nucleophiles dicyclopentadiene; nucleophiles stereospecific addn dicyclopentadiene; dicyclopentadiene stereospecific addn nucleophiles; platinum org compds; palladium org compds
IT Addition reactions
(of platinum dicyclopentadiene complexes)
IT 2,4-Pentanedione, platinum complexes
2,4-Pentanedione, 3-(3a,4,5,6,7,7a-hexahydro-4,7-methanoinden-5-yl)-, palladium complexes
4,7-Methanoindene-5-acetic acid, .alpha.-acetyl-3a,4,5,6,7,7a-hexahydro-, ethyl ester, platinum complexes
4,7-Methanoindene-5-malonic acid, 3a,4,5,6,7,7a-hexahydro-, diethyl ester, platinum complexes
Acetoacetic acid, ethyl ester, platinum complexes
Palladium, [6-(1-acetylacetonyl)-3a,4,5,6,7,7a-hexahydro-4,7-methanoinden-5-yl](2,4-pentanedionato)-, stereoisomer
Platinum, [6-(1-carboxyacetonyl)-3a,4,5,6,7,7a-hexahydro-4,7-methanoinden-5-yl](hydrogen acetoacetato)-, diethyl ester, stereoisomer
Platinum, chloro[6-(dicarboxymethyl)-3a,4,5,6,7,7a-hexahydro-4,7-methanoinden-5-yl](pyridine)-, diethyl ester, stereoisomer
Platinum, di-.mu.-chlorobis[6-(dicarboxymethyl)-3a,4,5,6,7,7a-hexahydro-4,7-methanoinden-5-yl]di-, diethyl ester, stereoisomer
Pyridine, platinum complexes
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
IT 12083-92-0 12294-98-3
RL: RCT (Reactant)
(addn. reaction of)
IT 100-46-9 105-53-3 123-54-6, reactions 141-97-9
RL: RCT (Reactant)
(addn. reaction of, with platinum dicyclopentadiene complexes)
IT 27832-21-9P 27832-22-0P **27832-23-1P**
RL: **SPN (Synthetic preparation); PREP (Preparation)**
(prepn. of)
IT **27832-23-1P**
RL: **SPN (Synthetic preparation); PREP (Preparation)**
(prepn. of)
RN 27832-23-1 HCAPLUS
CN 4,7-Methanoindan-5-amine, N-benzylhexahydro- (8CI) (CA INDEX NAME)